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A TAXONOMY OF REGULATIONS: THE EFFECT OF REGULATION ON
SELLING ACTIVITIES
by
John F. Riggs

ABSTRACT
Many companies are faced with rising numbers of regulations with which they
must comply. Regulations are particularly common in the areas of employment,
environmental protection, and licensing of businesses. In recent years, a growing trend of
new regulations has emerged in the selling and sales management business environment,
changing the nature and scope of salespeople’s jobs. How do regulations affect the way
salespeople do their jobs? This is an important and largely unexplored question.
Therefore, the purpose of this study is to empirically construct a taxonomy of regulations
that reveals their effect on current selling activities. A total of 7,493 observations were
obtained from pharmaceutical representatives via an electronic survey which served as
the basis for creating factor scores that were subsequently entered into a two-step cluster
analysis. The analysis produced a six cluster solution of regulations indicating distinct
taxonomic structures of regulations that affect selling activities. The resulting framework
is useful to researchers, and practitioners, who can view regulations in terms of the
degree to which selling activities are impacted.
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CHAPTER 1: INTRODUCTION
Many companies are faced with growing numbers of regulations with which they
must comply. In fact, there are one or more government agencies that oversee virtually
every part of a company’s organizational chart. Regulations are particularly common in
the areas of employment, health and safety, environmental protection, and licensing of
businesses: Environmental Protection Agency (EPA), Occupational Safety and Health
Administration (OSHA), Equal Employment Opportunity Commission (EEOC), and the
Federal Trade Commission (FTC) are examples of agencies responsible for regulating
such areas.
Costs associated with regulatory compliance have been reported to cause
significant burden on companies (Becht, Mayer, and Wagner 2008; Hahn and Tetlock
2008; Laeven and Levine 2009; Nicoletti and Pryor 2006; Weidenbaum 1998). The
seemingly wide spread growth of government regulations placed on businesses continues
to generate noticeable concern in the United States. Since 1980, the number of pages of
regulations in the Code of Federal Regulations has increased from around 1,000 pages to
over 25,000 pages, a 25-fold increase.
Rob Portman, a United States Senator from the state of Ohio, reported that beginning in
2005, a 60 percent increase in pending federal regulations, represents the highest number
recorded since the government kept count (U.S. Senate Committee 2011).
Today, there are 4,226 regulations in the pipeline (The Office of Information and
Regulatory Affairs 2011) of which the government has identified that more than 800
1
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affect U.S. businesses, an 11.9 percent increase over 2009. In a recent statement to
congress, The Office of Management and Budget (OMB), in accordance with the
Regulatory Right to Know Act (2000) produced a report that “summarizes estimates by
Federal regulatory agencies of the quantified and monetized benefits and costs of major
Federal regulations reviewed by OMB over the last ten years" (OMB, p.3). The details of
the report estimated $12.5 billion in annual costs by executive agencies to implement
regulations. The Code of Federal Regulations (U.S. Government Printing Office, 2011)
cataloged over 130,000 pages of regulations from just over 60 federal agencies. These
figures estimated that federal agencies generated/issued approximately 4,000 regulations
annually.
Despite the large number of annually issued regulations, virtually all the attention
has focused on regulatory agencies and regulatory impact at the firm level (Djankov,
McLiesh, and Ramalho 2006; Hahn et al. 2000; Hemphill 2006 Kolsarici and Vakratsas
2010). Such topics as compliance (Breaux and Vail 2006; Hahn and Litan 2005; O'Reilly
and Chatman 1986), legal (Hahn and Tetlock 2008; Peterson 1994), ethics (Bellizi and
Bristol 2005; Cavanagh 2004; Ferrell, Fraedrich, and Ferrell 2006; Zoghbi 2010) and
costs (Becht, Mayer, and Wagner 2008; Crain and Johnson 2001; Hahn and Tetlock
2008; Sidhu, et al. 2008) are discussed relatively frequently. However, regulatory control
is finding its way into functional areas within the firm. For example, a wide variety of
laws and sources regulate the marketing function, such as; antitrust laws designed to
protect consumers against predatory pricing schemes, consumer protection laws that
provide rules for product warranties and product liability, and intellectual property laws
that address issues related to patents, trademarks, and copyrights (Gollin, 2008; Lamb,

3
Hair, and McDaniel 2011; Pressey and Ashton 2009; Winn and Jondet 2008). Despite
these laws, adopted specifically to govern marketing, regulation is no longer unique to
the marketing function
Prior to April, 2003, selling efforts by life sciences firms such as medical device,
pharmaceutical, and biotechnology had experienced no formal regulatory control over
their selling activities. However, on May 5th, 2003, the Office of Inspector General
(OIG) issued the Compliance Program Guidance for Pharmaceutical Manufacturers
which prohibited many previously conducted selling activities. This program sparked the
beginning of a sequence of newly outlined controls, procedures, and regulations directed
at selling activities and customer interactions of life sciences companies.
Most recently, additional regulatory control has found its way into the selling and
sales management business environment as demonstrated by the 2009 Code on
Interactions with Healthcare Professionals published by the Pharmaceutical Research and
Manufacturers of America (PhRMA). The PhRMA Code is specific to the
pharmaceutical industry and regulates how pharmaceutical products and related prelaunch activities are to be conducted between company representatives and customers.
For the first time, complying with these codes requires salespeople to change the ways in
which they conduct selling activities and perform their jobs (Code on Interactions with
Healthcare Professionals 2009).
How do regulations affect the way salespeople do their jobs? This is an important
and largely unexplored question. Although considerable research has been devoted to
regulation of business at the firm level, companies need to understand the impact of
regulations on the selling environment in order to evaluate potential opportunities and
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threats during the decision process (Jones, Zoltners, and Weitz 2005). Regulations
intended to control selling activities are not industry specific. Numerous selling activities
are regulated in telecommunications, real estate, energy, tobacco, pharmaceuticals, and
financial services (Stremersch and Lemmens 2009). Rationale for regulating various
selling practices has been attributed to an increase in scrutiny by industry groups, federal
regulators, and consumer watchdogs on the practice of promotion and personal selling.
This increased scrutiny has resulted in a labyrinth of new laws, the issuance of revised
rules, and the creation of specific agencies designed to enforce compliance (Danzon,
Keuffel, and Rose 2005).
Given the current growth of regulatory control, and its potential impact on the
selling environment, adjusting with innovative approaches and adapting to new selling
processes is required for both practitioners and academic researchers (Jones, Brown, and
Zoltners 2005). Furthermore, the analysis of regulatory effects on selling is significant
since it may help regulators develop more effective policies. Therefore, by extending
taxonomy research to the sales and sales management literature, this dissertation seeks to
provide a means for organizing sales activities affected by regulations into classes or
groups that will be amenable to systematic investigation and theory development.
The following describes the order of this paper. First, classification frameworks
are examined coupled with background information on taxonomies. Thereafter,
regulation in business is reviewed, and since selling activities are impacted by the
presence of regulations (Corneliussen 2005), the literature on selling activities is given an
overview. Then, a description of the method employed to analyze the impact of
regulations on selling activities followed by results, discussion and conclusions will
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complete this study. The next section of this paper deals with the literature related to the
study.
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CHAPTER 2: LITERATURE REVIEW
The Need for a Taxonomy
Sokal and Sneath (1963) reported some of the earliest work on empirical
taxonomic schemes. They speculate that many fundamental advances in organizational
and social sciences were founded on such schemes and are necessary for progress in
science (Fleishman, Mumford, Zaccaro, and Stephen 1991). Additionally, taxonomies
provide researchers the required framework for hypothesis generation (Messick 1989),
vital structural components, and identify the foundation for theory development
(Fleishman, Quaintance, and Broedling 1984).
Salespeople are faced with growing numbers of regulations that impact their
selling activities. For example, three primary factors of selling; developing relationships,
promotional activities, and entertaining (Moncrief, Marshall, and Lassk 2006) are all
regulated at the Federal, State, or industry level in numerous industries. Hence, there are
regulations on gift-giving, site access, customer provided meals, online events, grants,
information sharing, and numerous other activities (Boedecker, Morgan, and Stoltman
1991; Corneliussen 2005). Examples include, Mount Sinai Medical Center's prohibition
on gift giving of any value by its vendors, regardless of industry. Also, the Jackson
Health System (JHS) in Miami, Florida, has a policy that requires; “all Vendor
Representatives, prior to engaging in any conversation or communication, for the purpose
of selling, marketing, or influencing a decision, must first become ‘registered’ with the
County as a ‘lobbyist’” (JHS Guidelines 2007).
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Another example is how the real estate industry regulates the sharing of
information. Because Realtors are bound by certain laws and regulations (Fair Housing
Act), they cannot tell clients everything they may want and need to know. Fair Housing
laws describe the primary function of a real estate agent as connecting or matching
customers with properties, not providing information about local household income,
demographics and environmental factors, which is also referred to as “steering”.
The high quantity of multifaceted and vague regulations not only makes it
difficult for companies to know when they are in compliance, but also how to make good
business decisions. Since many of these regulations have the force of law, are costly to
administer, and impact many of the activities used by salespeople, it is important that
selling organizations are able to organize, understand, and comply with them. Therefore,
the first step toward understanding the interaction between regulations and selling tasks is
to develop an acceptable and usable taxonomy for scholars and managers (McKelvey
1975).
To achieve this undertaking, this research constructs an empirically-based
regulations taxonomy. Clusters of federal and industry regulatory activities are the
classification basis for examining their effect on selling activities. The taxonomy aims to
provide a framework for novel investigation, expansion of theory, and development of
strategy in the area of sales and sales management.

Taxonomies and Typologies
Approaches to Classification
Taxonomies and typologies are two commonly used conceptual classification
systems (Smith 2002). A taxonomy is an "empirically derived classification of actual
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objects based on one or more characteristics, as typified by the application of cluster
analysis or other grouping procedures" (Hair et al. 2010). Bailey (1994) described that "a
taxonomy uncovers patterns within a set of empirical variables, creating internally
cohesive clusters or groups." Alternatively,
"a typology is a conceptually based classification of objects based on one
or more characteristics. A typology does not usually attempt to group
actual observations, but instead provides the theoretical foundation for the
creation of a taxonomy, which groups actual observations" (Hair et al.
2010, p.486).
Thus, “taxonomies are inductive and based on data, while typologies are deductive based
on theory and require testing for validation” (Hair et al. 2010).
Bailey (1994) describes advantages that accompany the development and
application of taxonomies, many of which promote the current study. Data integration is
assisted by taxonomies; their quantitative design provides more valid classifications than
the subjective nature of typologies; in addition, taxonomies produce variables with more
specific descriptions than typologies. However, Bailey (1994) warns that a taxonomy’s
efficacy can be restricted if the data quality is poor and its measures are incomplete. In
addition, interpreting taxonomies can be tricky according to Bailey, and cautions
researchers about issues related to inference and generalizing. However, "using careful
measurement procedures, taxonomies often provide greater understanding of the
classified phenomena due to their ability to group objects into (relatively) homogenous
classes" (Bailey 1994).
A taxonomy, in its purest form, is an inductive method that attempts to avoid any
a priori scientific conceptualization. Hence, the categories are determined by data. For
scholars, the result is a fresh classification scheme grounded in reality (Bunn 1993).
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Taxonomies in Business Research
Taxonomies in Business Research (Strategy, Buyer Behavior, Logistics, Sales)
Scholars have produced decades of research developing and applying taxonomies
to comprehend how firms gain strategic insights (Bowen 1990; Earl 2001; Hambrick
1984; Morrison and Roth 1992), how buyers behave (Bunn 1993; Cannon and Perreault
1999), how sales forces contribute to organizational performance (Homburg, Jensen, and
Krohmer 2008; Moncrief, Marshall, and Lassk 2006) or how organizations operate via
logistics (Autry, Zacharia, and Lamb 2008; Hambrick 1984). One such example within
the services marketing literature is Bowen's (1990) development of an empirically based
taxonomy of consumer's perceptions of services. An interesting outcome from Bowen’s
taxonomy showed that service managers stayed in a particular industry their entire career.
This implies that a narrow-minded approach to marketing may encumber creativity and
innovation, and so marketing insight is limited if services marketers do not look outside
of their individual industry. Because of this, a large number of typologies have been
constructed for grouping services. However, prior to Bowen’s work (cluster analysis)
these conceptualizations had not been previously studied.
Building on past efforts to categorize buying processes and situations,
taxonomical research is often used in consumer research (Bunn 1993). Understanding
customer buying behavior involves a complex set of issues confounded by many
situational factors (Cannon and Perreault 1999). For decades, research scholars and
marketing managers agree that customers "frame" problems in their own way (Puto 1987)
and follow self-guided "rules of thumb" to direct their actions in specific situations
(Newell and Simon 1972). To cope with the complexities of situations and the quantity
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of decisions needed to be made, the creation of buying pattern classifications (taxonomy)
are central to sustaining research and the establishment of marketing programs that work
(Bunn 1993). As an extension of efforts to create classification schemes of buying
decisions, Bunn (1993) identified six prototypical "buying decision approaches" through
an empirically based taxonomy development procedure, resulting in a framework that
views customers segments from the perspective of four fundamental buying activities.
The findings provide new variations allowing for conceptual extension of the literature as
well as being useful to marketing managers and researchers alike.
In recent years, the growing number of websites where consumers purchase and
resell products has generated a new area of consumer buying and consumption research;
consumer-to-consumer (C2C) purchase and resell behavior. Chu and Liao’s (2007)
taxonomy of consumer online resale behavior defined and specified how various
dimensions (i.e., “planned” or “unplanned resell”) impacts consumer’s behavior on
purchase and resale decisions. The authors posit that by examining consumer online
resale and purchasing behavior relationships, the taxonomy supplies a more
comprehensive picture of online consumer behavior (Chu and Liao 2007).
Another area in business research that has a history of developing and applying
taxonomies is business logistics. In all areas of today’s market place, an increase in
worldwide competition has burdened companies with an excess of supply over demand.
Therefore, the opportunity to make bad supply chain decisions is more present than ever
(Christopher, Peck, and Towill 2006). An obvious example can be made by examining
the execution of “just-in-time” delivery choices. At the outset, “just-in-time” delivery
may decrease inventory in the production facility, however transport costs and supplier
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inventory may increase. At first, this type of decision appeared to avoid cost at one
company, but could easily transfer increased costs to the supply channel as a whole. This
example provides the foundation for why investigators have proposed various supply
chain taxonomies to extend the present logistics research.
Jones (2005) proposes that as research in selling and sales management is
developing, it is important to appraise the field’s key models, theories, and activities.
Furthermore, he argues that current selling and sales management research remains based
upon decades old models and assumptions that “may need revision in light of rapidly
evolving demands in the marketplace.”
For example, the relationship between sales and marketing business units has been
investigated by many researchers (e.g., Biemans et al. 2010; Guenzi and Troilo 2007;
Homburg and Jensen 2007), however little is known about the existing varieties of
marketing and sales configurations. By identifying constructs that compose marketing
and sales structures, empirically identifying variations of marketing and sales
configurations, and developing a taxonomy, Homburg, Jensen, and Krohmer (2008)
illustrate how much variance exists between the attributes of marketing and sales roles.
Their findings suggest that the strength of the relationship between marketing and sales,
together with high levels of market knowledge, is the most successful framework.
The field of selling continues to be affected by changes in technology, customer
relationship development, and increased competition, among other environmental factors.
As such, the breadth and depth of professional sales positions, including the actual selling
activities and behaviors of selling have also changed significantly (Moncrief, Marshall,
and Lassk 2006). Moncrief argued
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"that continuing to routinely cite old taxonomies as though they still
adequately portray today's domain of selling simply is not good research,
nor does it adequately allow sales organizations and their managers to
advance successful selling and sales management in practice" (Moncrief,
Marshall, and Lassk 2006, p.64).
In response to outdated published sales position taxonomies (McMurray 1961; Moncrief
1986; Newton 1973), Moncrief, Marshall, and Lassk (2006), developed an up to date
taxonomy of sales positions that considered current selling activities and strategies.
By using an updated list of 105 sales activities that reflect contemporary selling
activities, the author’s identified six new categories compared to previous sales position
taxonomies (e.g., McMurray 1961; Moncrief 1986; Newton 1973). Consultative seller,
new business/channel development seller, delivery seller, sales support, and key account
seller are selling categories that more accurately reflect present sales jobs and their
related activities (Moncrief, Marshall, and Lassk 2006).
As demonstrated by the examples given, the importance of classification-oriented
research helps scholars and practitioners organize otherwise unsystematic set(s) of
complex phenomena by determining patterns and universal traits among groups.
McKelvey (1975) concludes his seminal article with,
"The basic inductive-deductive process of science does not work without
the phenomena under investigation being divided into sufficiently
homogeneous classes. Managers cannot use the fruits of science unless
they first can discern which of all the scientific findings apply to their
situation" (McKelvey 1975, p.523).
Because there are numerous approaches to the study of regulations, it is important
to be explicit about the focus of this research. For the rest of this paper, I discuss the
regulating efforts that are intended to facilitate marketing exchanges only, as it is these
that are germane to this study. Areas of particular relevance include customer
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interactions, presenting product information, competitive information sharing,
entertaining customers, gift giving, and grants.
Building on the review of taxonomies in business, the next section explores
regulation in business, specifically the areas of compliance and cost, including some
discussion on their impact. The section concludes with current examples of regulations
that control selling activities.
Regulation in Business
Compliance
In general, compliance is defined as “following” rules, requirements, guidelines,
standards or laws. Regulatory compliance fundamentally refers to “following” business
processes, procedures, and practices that are in agreement with sets of or agreed upon
norms (Lu, Sadiq, and Governatori 2008). In recent years, high-profile corporate
scandals involving companies such as WorldCom, Tyco, and Enron has produced new
types of challenges for companies concerning compliance. For example, effective
December 1, 2006, organizations are required to adapt their processes for electronically
stored information (ESI) during legal proceedings to the new Federal Rules of Civil
Procedure (FRCP). Consequently, all companies facing potential U.S. Court
investigation must comply with the new FRCP at once in order to avoid monetary fines,
unfavorable case rulings, and business loss.
In 2008, Microsoft Corporation, the largest software company in the world, was
fined by regulators of the European Union 899 million Euros (1.15 billion USD) for
noncompliance with a 2004 antitrust order (European Commission 2009). One year
earlier, DaimlerChrysler failed to meet U.S. federal fuel efficiency standards resulting in

14
$30 million USD fine (Environmental Protection Agency 2007). That same year, York
International Corporation, a global maker of heating, ventilating, air-conditioning, and
refrigeration products, was ordered to pay $12 million USD for violations of the U.S.
Foreign Corrupt Practices Act of 1977 (U.S. District Court 2007). These types of reports,
whereby companies incur significant fines for regulatory noncompliance have become
increasingly common, illustrate the importance of ensuring internal controls are in place
to address compliance with laws and regulations (Scholz 1984).
To further illustrate this point, over 1,300 executives responded to a 2005 Ernst &
Young survey stating that compliance with regulations exceeded “worms and viruses” as
the most important item when setting information security policy. For this reason,
corporations must make certain that personnel are conscious of and take steps to conform
to applicable laws and regulations. In response, companies are implementing regulatory
compliance frameworks that include compliance policies, standards, measures, and
training programs. The intended benefits of such an approach include the assurance of
corporate control of compliance activities, increased efficiencies, heightened worker
awareness of compliance standards, and the reduction of legal and financial risks
(Maignan, Ferrell, and Hult 1999).
Recently in 2010, the Food and Drug Law Institute (FDLI) approved disclosure
legislation requiring life sciences companies (e.g., pharmaceutical, medical device and
biotechnology) to report sales and marketing promotional expenses (FDLI 2011). This
action is the basis for compliance professionals to ensure sales organizations value the
significance of their activities and maintain compliance. According to the Food and Drug
Law Institute (2011), employee training, updated policies and procedures, inspections,
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and specific compliance strategies are necessary in today’s highly regulated business
environment.

Cost of Regulations
“Although regulations have no direct fiscal impact, they pose real costs to
consumers as well as businesses” (Hahn et al. 2000). As recent as 2008, the yearly
expenditure of federal regulations in the United States grew to more than $1.75 trillion
(Crain and Hopkins 2010). Of this amount, the annual direct burden on business is
estimated at $970 billion, or $8,086 per employee (Crain and Hopkins 2010). Included in
these costs are resources employed by government agencies to disseminate, monitor, and
enforce regulations, as well as the compliance activities by firms (OMB 2009).
The development of benefit-cost analysis tools has been the government’s
response to the soaring monetary costs of regulation (Hahn and Litan 2005). From the
perspective of improved efficiency, an example of benefit-cost analysis that enhanced the
effectiveness of regulation was the 1981 analysis of phasing out leaded gasoline. This
was the beginning of the Reagan administration’s plan to eliminate lead in gasoline. At
that time, Christopher DeMuth was the official in charge of reviewing the regulation, and
stated:
"A very fine piece of analysis persuaded everyone that the health harms of
leaded gasoline were far greater than we had thought, and we ended up
adopting a much tighter program than the one we had inherited. At the
same time, the introduction of marketable lead permits saved many
hundreds of millions of dollars from the cost of that regulation" (DeMuth
and Ginsburg 2010).
After several analyses, DeMuth and his colleagues reported that constricting the
lead standard in gasoline suggested over $15 billion (1983 dollars) would be saved over 4
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years (Hahn and Tetlock 2008). Three areas contributed to the overall savings; vehicle
maintenance, decreasing emissions, and reduction in lead-related health issues.
The prior example shows how regulation was improved by economic analysis.
However, Morrison, Winston, and Watson (1999) reported how governments also
implement regulations where costs exceed benefits. The Airport Noise and Capacity Act
of 1990 was studied five years after its inception (1995), and was found to cost over $5
billion in excess of its projected benefits. Unintended consequences of this regulation
included the replacement of 27 percent of the aircraft from U.S. airports earlier than
budgeted due to the new noise level limits. This unplanned replacement would cost
about $10 billion (1995 dollars).
The previous research suggests that estimating the payback and expenses of
individual regulations is not always straightforward. As seen in the case of leaded
gasoline, estimating payback can involve complex ways of thinking that connect
fundamental science to the wellbeing of individuals to the cost of those effects.
Likewise, expenditures are also complicated and hard to estimate since different
companies will respond in dissimilar ways regarding the evolution of technology, as seen
in the case of the Airport Noise and Capacity Act of 1990 (Morrison, Winston, and
Watson 1999). Hahn (2005) concludes that "it can be quite difficult to estimate how
regulatory policy will affect different segments of the population", signaling that the
quality of analyses of regulation does not meet the basic standards of economic research.
Apart from direct monetary costs, Weidenbaum (1998) argues that firms face
more subtle burdens as a result of regulations. Fundamental to these are effects on
competitiveness, innovation, and output. From this viewpoint, cost is seen in terms of an
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alternative that is given up as a result of a decision, suggesting that companies are willing
to take a "slap on the wrist" and pay a steep fine for not being compliant with regulations
because financially it is more profitable for the company. Kambhu (1989) notes when
companies have the resources to challenge penalties or hide its noncompliance, elevating
standards may drive compliance down, despite the consequences.
A common theme emerges from the various literatures on cost of regulations:
The process of compliance is both costly and time consuming, and many businesses face
significant challenges to keep up with the changing laws. The cost burden, both direct
and indirect, appears to be unchanging and continues to be a hurdle for businesses to
thrive and remain a vital part of our economy.

Regulation of Selling
The impact of regulations has received a lot of interest in finance and accounting
(e.g., Becht, Mayer, and Wagner 2008, Laeven and Levine 2009, Melis and Carta 2010;
Piotroski and Srinivasan 2008, Sidhu et al. 2008), economics (e.g., Disdier, Fontagne,
and Mimouni 2008), as well as marketing (e.g., Friedman and Gould 2007, Kolsarici and
Vakratsas 2010; Petty and Andrews 2008). However, prior business literature has
ignored the role of regulatory requirements in illuminating its impact on selling activities.
“The fact that sales forces represent a major investment for many firms, with the largest
sales forces spending billions of dollars a year to deploy and support tens of thousands of
direct salespeople and their activities” (Zoltners, Sinha, and Zoltners 2001), it makes this
area of study particularly interesting to academia and practice (Reece and Ahearne 2010;
Twomey, et al 2008).
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Selling Activities and Behaviors
The one fundamental trait that all sales people have in common is the activity of
selling. Regardless of the role or industry, sales people engage in selling activities and
these activities can be identified readily. Common selling activities include; building
trust with customers, sharing product information, overcoming objections, entertaining
customers, and gift giving (Moncrief, Marshall, and Lassk 2006). Additionally, work by
Reid, Plank, and Minton (1997) propose a useful means of conceptualizing sales as an
interpersonal communication process. The authors identify getting information, giving
information, and using information to reflect a communication orientation in selling
behavior.
Reid, Pullins, and Plank (2002) operationalized and tested these measures of a
salesperson’s communication behaviors for different types of purchase situations. The
authors reported that among the six purchasing situations used in their research; (1)
casual, (2) routine low priority, (3) simple modified rebuy, (4) judgmental new task, (5)
complex modified rebuy, and (6) strategic new task (Bunn 1993), differences were found
in the persuasiveness of the salesperson (Reid, Pullins, and Plank (2002). This research
suggests that a salesperson’s selling behavior is affected by external/environmental
situations, in this specific study by purchase situations.

Selling Activity Measure Development Procedure
The sales behaviors chosen for the current study were derived following the lead
from several authors. The process began by using the 121 sales activities developed by
Moncrief (1986) coupled with the model posited by Reid, Plank, and Minton (1997) that
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defined salesperson behaviors as those involved in “getting” information, “giving”
information, and “using” information. This view of sales behaviors is based on the
observation that communication is fundamental to the selling process (Reid, Pullins and
Plank 2002). Finally, the list was further refined from a series of personal interviews and
focus group sessions with salespeople and sales managers representing banking (NAICS
521110), real estate (NAICS 531210), pharmaceutical (NAICS 325412), and automobile
(NAICS 441110) industries because of their known high degree of regulation
(García‐Canal, and Guillén 2008).
Initial personal interviews were conducted at a large pharmaceutical company’s
annual national sales meeting in central Florida. The firm’s Vice President of Sales was
asked to randomly select six to eight associates from his sales organization to participate
in a focus group discussion regarding selling behaviors and activities. The discussion
was conducted in a hotel boardroom with three pharmaceutical sales representatives, two
district sales managers, and one key account manager. Each of the participants was
provided a list of Moncrief’s (1986) 121 selling behaviors and Reid, Plank, and Minton’s
(1997) 31 sales behaviors. The participants were asked to “circle” the activities that they
currently perform in their day-today job as a salesperson. Following this exercise, a
“semi-structured interview” focus group was conducted that allowed the interviewer to
probe and expand on the participant’s responses regarding the relevance each of the
activities has on their day to day job as a salesperson.
In addition to the focus group, a series of three phone interviews were conducted
with the Vice President of a major U.S. bank, an independent real estate agent, and the
owner of an automobile dealership respectively. Prior to each call, the participants were
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emailed Moncrief’s (1986) 121 selling behaviors plus Reid, Plank, and Minton’s (1997)
31 sales behaviors. Consistent with the focus group procedure, the phone interviewees
were asked to review the lists for relevance and application by “circling” the activities
they currently perform in their daily job as a salesperson. The interviewer individually
facilitated a “semi-structured interview” with each of the participants to explore and
develop the participant’s responses.

Classification of Selling Activities
The classification of an inclusive set of sales activities is a key step in the
taxonomy development process. Examining the general selling literature, Moncrief,
Marshall, and Lassk (2006), and Reid et al. (2002) propose a useful inventory of selling
behaviors/activities. In addition, by combining input from the focus group and personal
phone interviews of industry experts, the sales activities selected for the present study
were theoretically defined and developed as a means of identifying selling activities
impacted most by regulations. Three categories of activities were identified; (1) activities
that build relationships, (2) activities that facilitate the buying process (getting to buy),
and (3) activities that aid planning (appendix 6).
The first category, “relationship building”, is comprised of relational selling
behaviors that commonly create strong buyer-seller bonds. Behaviors such as asking
questions, listening, and participating in mutual disclosure have been shown to create a
strong buyer-seller relationship (Crosby, Evans, and Cowles 1990). In addition, the
regularity of person-to-person communication between the salesperson and customer in
the form of customer follow-up has also been acknowledged as a key determinant of
relationship building. Therefore, the “relationship building” selling activities category
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includes four measures adapted from Reid, Pullins, and Plank (2002); (1) ability to ask
probing questions, (2) listened to customer, (3) ability to make a charismatic presentation,
and (4) ability to work well with other people involved in the purchase, plus a fifth
measure, (5) follow up with customer, which was added by industry interview and focus
group participants.
The second category of selling behaviors, “getting to buy”, includes activities that
reflect a salesperson’s expertise, and relevant skills associated with knowledge of their
market, product, customers, and competition. The salesperson, for example, may use
their product knowledge to help customers link certain product attributes to their needs,
answer customer objections, or differentiate his/her product or service from the
competition. Therefore three “using information” behaviors and three “giving
information” behaviors from Reid, Pullins, and Plank (2002) were combined to create the
“getting to buy” category. The six “getting to buy” activities are; (1) gain participation
and got customer involved in the sales presentation, (2) ability to use analogies and
similes in his/her presentation to help customer see how it relates to his/her situation, (3)
ability to link his/her product or service attributes to customer needs, (4) able to
differentiate his/her product or service from the competition, (5) ability to do
“homework” on customer, and (6) ability to handle objections raised by customer. Boles,
Johnson, and Barksdale (2000) reported that a customer is not likely to invest the time or
effort necessary to build a selling relationship with a salesperson who lacks expertise in
his/her field.
The third and final category of selling behaviors is “planning”. The acts of
business planning, pre-call planning, searching out new leads, and targeting activities
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require significant amounts of salesperson time. Hence, a lack of planning forces some
salespeople to choose the customer they see next based on irrational, spur of the moment,
client pressures (Lodish 1971). For this reason, we combined four of Moncrief, Marshall,
and Lassk’s (2006) selling activities with two activities identified from our industry focus
groups for a combined list of six “planning” behaviors in category three. They are; (1)
search out new leads, (2) pre-call planning, (3) designing a sales plan, (4) administrative
activities and documentation, (5) conduct targeting activities, and (6) business planning.
Actual items are provided in Table 1.
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Table 1
Sales Communication Behaviors Measures (adapted from Moncrief, Marshall, and Lassk 2006; Reid,
Plank, and Minton 1997; industry interviews and focus groups)
Relationship Building
(Reid, Plank, and Minton 1997)
• Ability to ask probing questions
• Ability to ask situation questions to try and understand customer needs
• Used questioning to assess customer needs
• Ability to ask clarification questions
• Listened to customer
• Ability to make a charismatic presentation
• Ability to work well with other people who are involved in the purchase
(Adapted from industry interviews and focus groups)
• Follow up with customer
Getting to Buy
(Reid, Plank, and Minton 1997)
• Gain participation and got customer involved in the sales presentation
• Ability to use analogies and similes in his/her presentation to help customer see how it relates to
his/her situation
• Ability to link his/her product/service attributes to customer needs
• Could differentiate his/her product/service from the competition
• Ability to do “homework” on customer
• Ability to handle objections raised by customer
Planning
(Moncrief, Marshall, and Lassk 2006)
• Search out new leads
• Pre-call planning/ targeting
• Administrative activities/ documentation
(Adapted from industry interviews and focus groups)
• Conduct targeting activities
• Designing sales plan
• Business planning

The preceding list of sales communication behaviors (Table 1), are classified as
valid measures for examining the potential impact of regulations based on face validity
ratings by industry experts that included theoretical and practical considerations via focus
groups. From an objective perspective, the fact that each identified selling activity can be
directly linked to some form of regulation further demonstrates the proposed list of
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selling activities accurately represents the concept of interest; selling activities impacted
by regulations. Three categories of activities were identified; (1) activities that build
relationships, (2) activities that facilitate the buying process (getting to buy), and (3)
activities that aid planning (appendix 6).
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CHAPTER 3: METHODOLOGY
The approach used to build the current taxonomy of regulations that affect selling
activities, is modeled after the commonly accepted practice formerly put forward by
Hickson, Pugh, and Pheysey (1969), further developed by McKelvey (1975) and has been
applied amongst the social sciences (i.e., Bunn 1993; Homburg, Jensen, and Krohmer
2008; Moncrief, Marshall, and Lassk 2006). The standard system used to develop
empirical taxonomy contains four common steps: The first step identifies the variables to
be used to form the categories. Variables are typically derived from several sources. For
concepts not clearly specified in the literature, an iterative process of interviews and
focus groups are commonly used (Moncrief 1986, Moncrief, Marshall, and Lassk 2006).
The second step--measure development--then produces feedback and an empirical
foundation on which to specify the variables. In steps three and four, cluster analysis is
applied to the data to assemble the objects based on the distinctiveness they possess. The
final step "defines the clusters as the categories of the classification scheme-summarizing the similarities and differences across the categories" (Bunn 1993).
Figure 1 shows a five-step procedure for taxonomy development. The principal
analytical instrument in taxonomy development is cluster analysis, which assembles “a
sample of elements (in survey research, often the respondents) such that the statistical
variance should exhibit high internal (with-in cluster) homogeneity and high external
(between-cluster) heterogeneity” (Hair et al. 2010). The primary step in cluster analysis
is deciding which variables to use with which to group observations (McKelvey 1975).
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Therefore, this taxonomy of regulations that affect selling activities/ behaviors starts with
the discovery and measurement of applicable sales activities (table 1).

Figure 1
Procedure for the Development of an Empirical Taxonomy
STEP 1
SPECIFICATION
Methods
•
•

Review literature
Conduct in-depth interviews

STEP 2
MEASURE DEVELOPMENT
Methods
•
•

Assess reliability/ item-scale discrimination
Compute scale scores

STEPS 3 & 4
CLUSTER ANALYSIS & PURIFICATION PROCEDURE
Methods
•
•
•

Perform initial cluster analysis
Select number of clusters
Apply purification procedure

STEP 5
MEASURE DEVELOPMENT
Methods
•
•

Assess reliability/ item-scale discrimination
Compute scale scores
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Conceptual Model
To construct the functional taxonomy, we must broadly characterize the subject
area by selecting items pertinent to our area of study, for this project, regulations.
Therefore, the initial step in creating the proposed regulatory taxonomy of selling
activities is to develop a typology of regulations that encapsulate the field of sales and
promotion. For this paper, the pharmaceutical industry was selected as the primary area
of study. This industry is known for its high level of regulation, including all stages of
product life-cycles, including promotion and selling activities. Examples include; sales
representatives are prohibited from providing items for healthcare professionals’ use that
do not advance disease or treatment education, such as; pens, note pads, mugs, and
similar “reminder” items with company or product logos (PhRMA 2009). Another
example states that companies are prohibited to provide recreational or entertainment
events in conjunction with promotional and/or educational meetings with customers (OIG
2006).
The complete typology developed here (Appendix 1) is a conceptually based
classification of regulations based on a broad set of federal, state, industry, and firm
regulations, thereby ensures that an inclusive list of regulations is incorporated, and
reducing the risk of omitting a key regulation. Additionally, only relevant conceptual
domains were covered in an effort to keep the number of variables parsimonious. The
typology does not attempt to group actual observations, but instead provides the
theoretical foundation for the creation of the proposed taxonomy, which will group actual
observations.
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Toward this end, a two-step selection process was used. First, to identify the
conceptual domains and to attain conceptual breadth, websites were reviewed (i.e.,
aba.com; fda.gov; ftc.gov; oig.hhs.gov; phrma.org), coupled with personal conversations
with select industry executives. Second, the core constructs contained within each
conceptual domain were selected. Constructs were deemed as core if their relevance was
consistently emphasized in the literature, if they were theoretically grounded, and if they
applied across companies within the pharmaceutical industry. The two-step collection
procedure revealed a total of ninety-four (94) “core” regulations (Appendix 2). The list is
comprised of thirty-six OIG, thirty-one PhRMA, nine state, two from the District of
Columbia, and sixteen firm regulations (figure 2).
Figure 2
Initial Categories of “Core” Regulations

Source

Number

Office of Inspector General (OIG)
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Pharmaceutical Research and Manufacturers of America
(PhRMA)
States
Massachusetts
Maine
California
Nevada
South Dakota
Vermont
-------------------------District of Columbia

31

Firms
Company A
Company B
Company C
Company D
Company E
Company F
TOTAL

2
1
2
2
1
1
2

3
4
1
2
4
2
94
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Conceptual Domains
As appendix 1 indicates, regulations in the pharmaceutical industry are
constituted by four conceptual domains. Each domain contains core constructs based on
relevance. The order of the domains in appendix 1 does not suggest a hierarchical
structure, especially not in the sense that one domain is a functional prerequisite of
another; however, they are not completely unrelated. Thus, conceptually, there is an
interdependent relationship between domains.
The first conceptual domain is federal regulations. It contains government
agencies that are the primary regulators of marketing and sales activities of
pharmaceutical firms. The three core primary agency constructs are; (1) The Office of
Inspector General (OIG) of the Department of Health and Human Services, which
provides compliance procedures for the health care industry. (2) The Federal Trade
Commission (FTC), which handle matters affecting consumer protection and competition
jurisdiction, and (3) The Division of Drug Marketing and Communication (DDMAC) of
the U.S. Food and Drug Administration (FDA), whose mission is “to protect the public
health by assuring prescription drug information, is truthful, balanced and accurately
communicated.”
The second conceptual domain is state regulations. Currently, six states, and the
District of Columbia are identified as having specific regulatory controls that impact
selling activities of pharmaceutical companies. They are; Massachusetts, Maine,
California, Vermont, South Dakota, Nevada, and the District of Columbia. The
remaining forty-five states do not possess individual regulatory controls and only require
compliance at the federal level.
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The third conceptual domain is industry regulations. The Pharmaceutical
Research and Manufacturers of America (PhRMA) represents the country’s foremost
pharmaceutical research and biotechnology companies. Their mission is “to conduct
effective advocacy for public policies that encourage discovery of important new
medicines.” To that end, PhRMA “developed and enforces regulations that govern
interactions with healthcare professionals that relate to the marketing of products”
(PhRMA.org).
The final conceptual domain is firm self-regulations. Pharmaceutical firms have
developed and implemented numerous internal controls, procedures, and regulations that
promote adherence to requirements of the federal health care program (FDLI 2010).
Recognizing that federal guidelines are intended to provide guidance, and often lack the
force of law, firms attempt to self-regulate their activities by developing and enforcing
numerous internal self-regulations by means of corporate compliance programs. These
programs monitor all agents of the sales and marketing function to prevent and detect
violations of law or company policy.
As the OIG calls for in its Guidance (OIG 2003), pharmaceutical firms tailor their
corporate compliance programs to fit the unique environment of their company, whether
it is pharmaceuticals, devices, or diagnostics (Endo 2012; Par 2012; Sanofi 2012). Once
companies become aware of possible violations of company policy or law, internal
investigations are initiated. Disciplinary action, where appropriate, is taken along with
any corrective measures to deter possible future violations.
The Office of Inspector General (OIG) federal guidelines for pharmaceutical
manufacturers and The Pharmaceutical Research and Manufacturers of America Code on
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Interactions with Healthcare Professionals (PhRMA) are listed in appendix 3. Both the
OIG guidelines and PhRMA code regulations are taken directly from their respective
published documents. The five states (MA, ME, CA, NV, SD, VT) and the District of
Columbia regulations were taken directly from their respective Office of the Attorney
General websites (http://www.atg.state.ma.us, http://www.atg.state.me.us,
http://www.atg.state.ca.us, http://www.atg.state.nv.us, http://www.atg.state.sd.us,
http://www.atg.state.vt.us, and http://www.dc.gov) and are listed in appendix 2.

Final Typology of Regulations for this Study
The final typology of regulations was derived by subjecting the entire list of
ninety-four “core” regulations to series of content and face validity checks, which
produced an inventory of fifty-nine regulations representative of the area being studied.
Finally, to check for inter-rater reliability, one regulation that fell outside of the
categories of regulations presented was added, for a total of sixty regulations used for this
study. The following discussion describes the steps used for constructing the final
typology of regulations.
The initial step in developing the regulations taxonomy was to subject the entire
list of ninety-four (94) core regulations (OIG, PhRMA, State, and firm) to thorough
content analysis, remove replica items and ensure the list only includes unique
regulations that were relevant to the area of study and effectively represent the subject
area. A panel of eight pharmaceutical industry experts (one Vice President of Sales, two
Regional Sales Directors, four Critical Care Sales Representatives, and one Human
Resources Manager) was assembled to examine a combined list of thirty-six OIG, thirty-
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one PhRMA, nine state, two District of Columbia, and sixteen firm regulations (n=94).
They were asked to identify duplicate items, validate only those regulations that applied
to the sales function, and unanimously agree on a final list of regulations that accurately
reflect their current industry landscape.
This iterative process of specification and comparison by eight pharmaceutical
industry experts collectively identified six federal, two industry, nine state, two District
of Columbia, and sixteen firm regulations as either extensions or duplicates of existing
federal and industry regulations. These thirty-five regulations were therefore combined
and eliminated from the finalized list, which included the nine state, two District of
Columbia, and sixteen firm regulations, which completely removed the state and firm
domains from the final typology. As a result, the final typology of combined regulations
contains a complete and parsimonious set of fifty-nine unique regulations described in
two domains; federal and industry (Appendix 4). The complete list of regulations used in
this study is found in Appendix 5.

Survey Instrument
Once the sales activity list and the inventory of relevant regulations were created,
the original survey was formulated to determine the relative significance of each known
regulation and its perceived effect on the identified selling activities based on
pharmaceutical sales representative perceptions.
Using a seven-point Likert scale (-3 very negatively, -2, -1, 0 not at all, +1, +2, +3
very positively), respondents were asked to individually rate each regulation's effect on
their ability to perform the seventeen identified selling activities. A balanced (equal
number of positive and negative response choices), bipolar (negative to positive; -3 to +3)
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scale was used due to the opposite attributes of the dimensions being studied (Schwarz
1999). Since the notion being measured is not a range with the low end of the scale
representing the absence of the attribute, and instead uses two poles describing opposite
attributes (“very negatively” and “very positively”), the bipolar numeric properties of the
scale were chosen. Furthermore, it appeared logical to use a numbering convention that
was in concurrence with the nature of the questions so respondents would not be left to
interpret the meaning of the questions (Schwarz et al. 1991). Without providing negative
scores, it was anticipated that subjects may interpret an “all positive Likert scale” (1 to 7)
as having only a positive impact, and not the presence of negative impact.
Since the questionnaire was developed for the purpose of this study, the
instrument was pretested with pharmaceutical sales representatives. Representatives
were asked to examine questions for completeness, in other words, the degree to which
the list of items effectively encompassed selling activities within the categories of
regulations presented. They were also invited to identify any doubt, oversight, or other
obscurity when answering each activity item, and also to offer ideas for survey
improvement (De Vaus 2002). To test for face and content validity, the preliminary
survey containing the complete list of fifty-nine regulations and twenty selling behaviors
was appraised by eleven first-line sales managers and twenty-six sales representatives
attending their company national sales meeting in the northeastern United States.
In addition, one retired and four current senior level pharmaceutical executives,
who were not employees of the sample frame, appraised the survey from the perspective
of specificity, readability, accuracy, and internal and external validity. Based on
feedback, three sales communication behavior measures (“ability to ask situation

34
questions”, “used questioning to assess customer needs”, and “ability to ask clarification
questions”) were removed since they were deemed duplicative and redundant. Hence, the
removal of these three behaviors from the original twenty measures produced a revised
total of seventeen items. Finally, to measure inter-rater reliability, one regulation was
added to the original fifty-nine that fell outside of the categories of regulations presented;
“Speakers and their materials must clearly identify the company that is sponsoring the
presentation.” This question was independently coded and used to compare the degree of
agreement among raters.
To assess the generalizability of the study, and to establish inclusion criteria for
participants, the final survey included queries about respondent job title, position, and
qualified experience. A website was used as placement for the survey to facilitate ease of
data gathering.

Randomized, Multicenter, Parallel-Arm Clinical Research Trial Design
Given our research objective of empirically developing a taxonomy of sixty
identified regulations that accurately reflect their effect on seventeen recognized selling
activities, the projected questionnaire would contain 1,020 items. Clearly, the issue of
questionnaire length became a major concern. With such an extensive survey,
“respondents might not answer properly at later stages of the questionnaire or may stop
filling the questionnaire out” due to respondent fatigue and boredom (Berdie 1989).
Based on strong conceptual support predating the application of the technique, the
primary investigator felt that the number of regulations and the number of selling
activities could not be reduced (Hair et al. 2010). Therefore, we propose a method used
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by medical researchers (Appel 2006; Localio et al. 2001). "Randomized, multicenter,
parallel-arm clinical research data gathering design", as an effective tool to reduce
respondent burden without making trade-offs between the amount and quality of
information obtained.
Medical researchers commonly use more than one medical center or clinic to
gather clinical trial data. This method is known as “multicenter research trial” design. In
addition, multiple treatment groups (“arms”) are established to test at least two
medications (e.g., treatment A and treatment B). Study participants are randomly
assigned one of the respective treatments. This type of study design using “parallelarms” provides remarkable efficiency by testing multiple treatments in identical
populations simultaneously (Appel 2006). The sample size is typically similar across
parallel arms such that there is no interaction linking treatments. Hence,
“if there is no interaction between therapies, then one can test the effect of
treatment A by combining the results across groups, regardless of whether
they receive treatment B. Likewise, one can test the effect of treatment B
by combining the results across groups, regardless of whether they receive
treatment A” (Appel p.1360).
Due to the large number of required subjects, most large clinical trials are conducted at
numerous clinical research centers.
A key requirement when conducting a multicenter, parallel-arm research trial is
the establishment of patient or subject “inclusion criteria”. Inclusion criteria are a
method of establishing precision in your cohort. In medical research for example, the
investigator might suspect that a new brand of hypertension medicine is more effective
than an existing brand, but for some reason this seems to be true only for female patients
that are over 60 years of age with a history of diabetes and smoking. Based on this
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information and the investigator's professional knowledge, he can establish specific
inclusion criteria for his study. More specifically, inclusion criteria are the criteria or
standards that specify which subjects are to be included in the study lending to increased
generalizability. In medical research trials, inclusion criteria may include demographic
data, previous medical history, disease states being investigated, and related medical
conditions. “Inclusion criteria help identify suitable participants” (Agency for Healthcare
Research and Quality AHRQ.gov). It is necessary that these criteria be objective and
clearly defined, so that those involved in the study (or investigators trying to duplicate the
study) can replicate participant inclusion decisions accurately.
In summary, randomized, multicenter, parallel-arm trials allow clinical
investigators to include larger numbers of participants, longer data gathering tools such as
surveys, diverse geographic locations, the inclusion of broader population groups, and the
ability to compare results among participants, all of which increase the generalizability of
the study (Localio et al. 2001). The current study is a randomized, 3-arm parallel group,
multicenter study assessing the effect of regulations on selling activities in
pharmaceutical sales representatives. It mirrors randomized, multicenter, parallel-arm
research trial design methodology with inclusion criteria standards, thereby permitting us
to collect responses from three separate arms (surveys), and test and combine a large
number of observations (n=7493), regardless of which survey the respondent received
(Appel 2006; ACRP 2012). This method is unknown in marketing research and is
therefore a new alternative to the heuristic methods that are currently used when massive
questionnaires are used.
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The Questionnaire
The initial survey instrument contained sixty (60) regulations of which
respondents would be asked to rate each of the seventeen (17) selling activities. In order
to reduce “respondent burden” and reduce survey length, multicenter, parallel-arm
research trial design methodology and inclusion criteria standards were applied which
divided the original list of sixty (60) regulations into three separate surveys containing
twenty (20) regulations each. A random number generator was used to create a sequence
of twenty (20) regulations coupled with the same selling activities in order to develop
three respective questionnaires that lack any pattern. Each respondent was asked to rate
seventeen (17) identical selling activities based on the impact of the twenty (20)
respective regulations listed. In addition, each version contained the same demographic
questions, and descriptive variables at the firm level. Exactly twenty (20) regulations,
one-third of the complete list, appeared on each of the three versions of the survey;
therefore, all respondents did not complete all scales. Each of the three versions of the
survey is found in appendix 7.

Sample Frame and Primary Data Collection
Subsequently, the next phase in the process of taxonomy development is to gather
data for the purpose of dividing the sample into meaningful groups. As outlined in the
conceptual model, primary data collection was from the pharmaceutical industry.
Pharmaceutical firms are highly regulated in nearly all stages of the product life-cycle,
including promotion and selling activities, which provide an appropriate data source and
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sample for this research (Danzon, Keuffel, and rose 2005). Hence, the pharmaceutical
industry provides a good context in which to develop and test this model.
In keeping with the multicenter, parallel-arm clinical research trial methodology,
a feasibility study was performed. A feasibility study is typically performed as part of the
planning process before the initiation of a new clinical study (Hagen et al. 2011). One of
the biggest challenges of initiating a new clinical research trial is the identification and
recruitment of the appropriate patient population for the study. The feasibility sample
frame for this study consisted of phone interviews with company officials from six
respective pharmaceutical firms. The interviews were used to ascertain the level of
response, company interest, and ability to satisfy a pre-established set of participant
inclusion criteria. A subject may be included in the study if all of the following criteria
are met:
Inclusion Criteria:
1. Currently employed by a pharmaceutical firm that is a member of the
Pharmaceutical Research and Manufacturers of America Association (PhRMA).
Since PhRMA regulations are a key aspect of this study, this criterion is necessary
for inclusion since not all pharmaceutical companies are members of PhRMA.
By requiring participants to be currently employed by a pharmaceutical company
that is a member, we ensure that all respondents are subject to the regulations
being studied.
2. Currently works as a salesperson, account representative, managed care
representative, or marketing manager. This criterion was established to ensure
all respondents currently work in a capacity that is directly impacted by sales and
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marketing regulations. Since our area of study is not appropriate for “jobs”
outside of the sales function, this condition safeguards against the inclusion of
respondents who would not be suitable participants.
3. Works in primary care, specialty, hospital, or account management division.
Pharmaceutical firms typically have numerous “divisions” that target unique
customer segments, support different company functions, etc. These four
divisions include the majority of sales representatives and the regulations being
studied. Therefore, it was important to specify “divisions” that are subjected to
the regulations being studied in order to exclude divisions that are not. (For
example: contracting, medical affairs, and distribution.)
4. Successfully completed a training program on “pharmaceutical promotional
practices and guidelines”. This criterion ensures that respondents have a similar
level of awareness of the regulations and understands expectations regarding
compliance. This standard removes the possibility of a respondent not being
previously aware of the regulations being studied.
For construction of the taxonomic system described here, only pharmaceutical
salespeople who met all of the above inclusion criteria were used. A sample of 489
pharmaceutical sales representatives was randomly drawn from a large U.S.
pharmaceutical firm that employs 1,000 sales professionals. A total of 396 completed
surveys were submitted via a website generating an overall response rate of 80.9 percent.
After surveys with more than 5 percent of missing data were removed (Little and Rubin
1989; Acuna and Rodriguez 2004), 381 usable surveys were left, producing an effective
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response rate of 77.9%. The remaining data from the 381 surveys were used to create the
taxonomy. Respondent demographics are reported in the table 2 below.
Table 2
Demographic Profiles of All Respondents, by Individual Survey
All
Respondents

Questionnaire
1

Questionnaire
2

Questionnaire
3

Gender
Female
Male

189 (49.6%)
192 (50.4%)

63 (51.2%)
60 (48.8%)

65 (51.2%)
62 (48.8%)

61 (46.7%)
70 (53.4%)

18 to 25 years
26 to 35 years
36 to 45 years
46 and older

90 (23.6%)
100 (26.2%)
86 (22.6%)
105 (27.6%)

28 (22.8%)
36 (29.2%)
26 (21.1%)
33 (26.8%)

26 (20.5%)
36 (28.3%)
30 (23.6%)
35 (27.6%)

36 (27.5%)
28 (21.4%)
30 (22.9%)
37 (28.2%)

Education
Associates Degree
Bachelors Degree
Masters Degree
Doctoral Degree

0 (0%)
159 (41.7%)
213 (55.9%)
9 (2.4%)

0 (0%)
54 (43.9%)
65 (52.8%)
4 (3.3%)

0 (0%)
54 (42.5%)
70 (55.1%)
3 (2.4%)

0 (0%)
51 (38.9%)
78 (59.5%)
2 (1.5%)

MD
ARNP
RN
LPN
Paramedic (PMD)
EMT
Cath Lab Tech
Lab Tech

1
5
15
5
3
3
1
1

0
2
5
1
1
1
0
0

0
2
6
2
1
1
0
0

1
1
4
2
1
1
1
1

Selling Experience
Less than 1 year
1 to 5 years
6 to 10 years
11 to 15 years
16 to 20 years
More than 20 years

31 (8.1%)
114 (29.9%)
86 (22.6%)
56 (14.7%)
56 (14.7%
38 (9.9%)

8 (6.5%)
28 (22.8%
23 (18.7%)
19 (15.4%)
24 (19.5%)
21 (17.0%)

11 (8.7%)
25 (19.6%)
35 (27.6%)
26 (20.4%)
20 (15.7%)
10 (7.9%)

12 (9.2%)
61 (46.6%)
28 (21.4%)
11 (8.4%)
12 (9.2%)
7 (5.3%)

Age

Education Other
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All
Respondents

Questionnaire
1

Questionnaire
2

Questionnaire
3

Industry Experience
Less than 1 year
1 to 5 years
6 to 10 years
11 to 15 years
16 to 20 years
More than 20 years

51 (13.4%)
114 (29.9%)
96 (25.2%)
53 (13.9%)
47 (12.3%)
20 (5.2%)

9 (7.3%)
34 (27.6%)
23 (18.7%)
19 (18.7%)
23 (18.7%)
15 (12.2%)

16 (12.6%)
33 (25.9%)
37 (29.1%)
20 (15.7%)
17 (13.3%)
4 (3.1%)

26 (19.8%)
47 (35.9%)
36 (27.4%)
14 (10.7%)
7 (5.3%)
1 (0.7%)

Company Experience
Less than 1 year
1 to 5 years
6 to 10 years
11 to 15 years
16 to 20 years
More than 20 years

107 (28.1%)
123 (32.2%)
86 (22.6%)
35 (9.2%)
28 (7.3%)
2 (0.5%)

24 (19.5%)
45 (36.6%)
25 (20.3%)
16 (13.0%)
11 (8.9%)
2 (1.6%)

27 (21.3%)
38 (29.9%)
37 (29.1%)
12 (9.4%)
13 (10.2%)
0 (0.0%)

56 (42.7%)
40 (30.5%)
24 (18.3%)
7 (5.3%)
4 (3.0%)
0 (0.0%)

Northeast
Southeast
Caribbean
Central U.S.
North Central U.S.
Southwestern U.S.
Northwestern U.S.
Nationally (entire U.S.)

73 (19.2%)
99 (25.9%)
7 (1.8%)
29 (7.6%)
64 (16.8%)
40 (10.4%)
56 (14.6%)
13 (3.4%)

24 (19.5%)
32 (26.0%)
3 (2.4%)
9 (7.3%)
18 (14.6%)
14 (11.3%)
19 (15.4%)
4 (3.2%)

26 (20.5%)
33 (25.9%)
3 (2.4%)
9 (7.1%)
19 (15.0%)
14 (11.0%)
19 (14.9%)
4 (3.1)

23 (17.5%)
34 (26.0%)
1 (0.8%)
11 (8.4%)
27 (20.6%)
12 (9.2%)
18 (13.7%)
5 (3.8%)

College Major
Marketing
Finance
Accounting
Sales
Education
Psychology
Health Related
Computer Science
Other

137 (35.9%)
35 (9.2%)
19 (5.0%)
19 (4.9%)
11 (2.9%)
18 (4.7%)
90 (23.6%)
4 (1.0%)
48 (12.6%)

52 (42.3%)
6 (4.9%)
8 (6.5%)
0 (0.0%)
8 (6.5%)
4 (3.2%)
24 (19.5%)
2 (1.6%)
19 (15.4%)

42 (33.1%)
13 (10.2%)
11 (8.7%)
3 (2.4%)
2 (1.6%)
6 (4.7%)
31 (24.4%)
2 (1.6%)
17 (13.3%)

43 (32.8%)
16 (12.2%)
15 (11.4%)
1 (0.8%)
1 (0.8%)
8 (6.1%)
35 (26.7%)
0 (0.0%)
12 (9.2%)

Region
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CHAPTER 4: DATA ANALYSIS AND FINDINGS
Results
Reflecting the process used by Moncrief, Marshall, and Lassk (2006), the
qualitative stage of our data analysis was followed by a two-step quantitative analysis:
factor analysis and cluster analysis. Primary groupings of the data were initially
identified using factor analysis, followed by cluster analysis to create the actual
regulation taxonomy. Other analyses, primarily cross-tabulations, were executed
throughout the procedure to help describe and clarify the individual clusters (Moncrief,
Marshall, and Lassk 2006).
Using the multicenter, parallel-arm clinical trial data gathering method,
aggregating or "stacking" the responses from three individual questionnaires, generated a
three-dimensional data set whereby each survey includes approximately one-third of the
7,493 total observations generated by 381 respondents. It was necessary to convert the
original three-dimensional data set into a two-dimensional measure in order to accurately
factor analyze the overall sample.
This conversion was accomplished by pooling the respondent’s ratings for each of
the seventeen respective selling activities by individual questionnaire. The pooled data
was then calculated into means for the purpose of creating more reliable and valid
measures (Gomez-Mejia, Tosi and Hinkin 1987; Zajac 1990). To illustrate the process,
one hundred twenty-three respondents rated seventeen selling activities for regulation
one, which created a three-dimensional data set. Means were then calculated by
averaging each of the one hundred twenty-three responses per individual selling activity
to generate a measure for each regulation by selling activity. More specifically, on a 7-
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point Likert scale, the average rating of one hundred twenty-three respondents regarding
the impact regulation one has on selling activity one is 4.00813. Likewise, using the
same scale, the average rating of one hundred twenty-three respondents regarding the
impact regulation two has on selling activity one is 4.01626. This methodology was
applied to the entire sample of three hundred eighty-one respondents and then, as with the
Moncrief (1986) study, the means were used as the clustering basis.

Factor Analysis
To generate meaningful categories (in this study, regulations affecting selling
activities), factor analysis using SPSS 17.0 was executed. An unweighted least squares
model with an oblique rotation was specified to minimize further bias and allow
correlation.
The scree plot (figure 3) indicated a three-factor model. The explained variance
by the three factors was 82.6 percent. A score of .4 was used as a cutoff to indicate
inclusion in a factor. As shown in table 2, fifteen of the seventeen indicators clearly
loaded on one of the three factors. Variables v1, v2, v3, v4, and v16 highly loaded on
factor one; variable two is characterized by variables v5, v6, v7, v8, v9, and v10; and
factor three has four distinctive characteristics (v11, v12, v13, v14). As shown, v15 and
v17 have significant loadings on factors two and one respectively. Since two variables
are given on both of these factors, v15 and v17 were deleted from the analysis (Hair et al.
2010). As noted in the table, the factor structure for the remaining fifteen variables is
now well defined, representing three distinct groups of variables that are consistent and
theoretically supported for the purpose of later cluster analysis.
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Table 3
Activities Affected by Regulations Factor Analysis

Pattern Matrix Maximum Likelihood Analysis Oblimin Rotation Factor¹

Customer Relationships
through Communication

Core Selling
Skills

Planning

Indicator
Ability to ask probing questions (v1)

.934

Listened to Customer (v2)

.942

Ability to make a charismatic presentation (v3)

.887

Ability to work well with others involved in purchase (v4)

.859

Follow up with customer (v16)

.900

Gain participation and got customer involved (v5)

.427

Ability to use analogies and similes in presentation (v6)

.628

Ability to link product attributes to customer needs (v7)

.565

Could differentiate product/service from competition (v8)

.587

Ability to do "homework" on customer (v9)

.592

Ability to handle objections raised by customer (v10)

.405

Search out new leads (v11)

.414

Pre-call planning/targeting (v12)

.638

Conduct targeting activities (v13)

.739

Designing sales plan (v14)

.451
.521

Business planning (v15)
Administrative activities/documentation (v17)

.462

Note. Bolded items represent cross-loadings and were therefore eliminated from the analysis
¹Loadings less than .40 are not shown and variables are sorted by highest loading

.505

.455
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Figure 3

Description of the Factors
Following the preliminary selling activity groupings, each group was examined
and given a name that identifies it by the correlating nature of the selling activities (Hair
et al. 2010). The following three selling activity groups emerged from the factor
analysis.
Factor 1: “Customer Relationships through Communication" (activities x1, x2,
x3, x4, x16). The five items that load onto factor 1 relate to activities associated with
building relationships with customers through relational communication skills such as
asking questions, listening to the customer, ability to make a charismatic presentation,
and follow-up with the customer. Thus, this factor was labeled “customer relationships
through communication.” Building customer relationships through communication
focuses on the “process” of communication (i.e., the how rather than the what), and is
maximized by brief social encounters, as well as, longer, ongoing interactions (Grissom,
Erchul, and Sheridan 2003).
Factor 2: "Core Selling Skills" (activities x5, x6, x7, x8, x9, and x10). Factor 2
involves activities that lead prospects toward the purchase of a product or service by
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changing customer perceptions through reason or figurative means. This factor is
comprised of six activities that represent foundational selling skills such as linking
products to customer needs, differentiating products from the competition, ability to
handle customer objections, and the ability to use influential presentation skills to relate
to customer needs. Factor 2 was therefore labeled “core selling skills”. Sales people
make use of these “core selling skills” as a way to change customer perceptions and
influence customer decision making.
Factor 3: “Planning” (activities x11, x12, x13, and x14). Items for factor 3
identified selling activities that help sales people prepare for customer interactions. The
act of “planning” for a salesperson is much like “pre-game” activities for sports teams.
These are the activities that build a structured understanding that sales people use to
become organized, mentally prepared, and solve problems so that everything is “routine”
when the sales person is in front of a customer (game-time). Prospecting skills such as
searching out new leads, pre-call planning, conducting targeting activities, and designing
a sales plan are the selling activities that created Factor 3.
By factor analyzing selling activities from a regulatory impact point of view, we
obtained three distinct groups (factors) which generated a novel way to organize selling
activities (appendix 8). While the three factor solution reported here generated
meaningful categories, it is important to note that the results are specific to the industry
studied (pharmaceutical) and represent the interaction between identified regulations and
selling activities. As such, our results do not represent generalizability and are subject to
empirical validation using other industries with similar regulations.
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Cluster Analysis
The objective of the clustering stage was to group different regulations into
descriptive classifications. Due to our large data set (7,493 observations) and the need to
vary large numbers of clusters, the two-step clustering approach, developed by Chiu et al.
(2001) was chosen to develop the taxonomy. “Unlike hierarchical clustering which
requires a matrix of distances between all pairs of cases, and the k-means algorithm that
requires "shuffling" objects to and from clusters” (Norusis 2008), the SPSS TwoStep
Cluster Analysis requires only a single pass of data, and can produce solutions for large
data sets for varying numbers of clusters.
Within SPSS 17.0, the two-step cluster method relies on the "auto clustering"
procedure when shaping the number of clusters that represents the data sample. The
calculation first measures the lowest Schwarz Bayesian Information Criterion (BIC), and
then the algorithm adjusts the result by considering solutions with a large "Ratio of
Distance Measure", thus generating the optimal number of clusters. Replication studies
have shown that BIC and AIC in combination (Two-Step Cluster) work better than BIC
or AIC alone (SPSS 2001). The analysis created six definite clusters which will be
described and discussed in the following section.
When performing a two-step cluster analysis within SPSS 17.0, the investigator
has the opportunity to supersede the "auto-clustering" default and perform any number of
cluster iterations as a cross-validation procedure to corroborate the appropriate number of
clusters for the final cluster solution. After five iterations, the procedure was terminated
because none of the observations changed membership and the clusters were stable (Bunn
1993).
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Moreover, cross-tabulations were performed, crossing each regulation by selling
activity, cluster, and a number of demographic variables. The cross-tabulations added
value when clarity was needed in interpreting the clusters. Group (cluster) association
after this process was the final assignment of the observations to clusters. In the
following results section, we list the major factors that play a part in defining each of the
six clusters - either positively, negatively, or no role at all.

Classification and Interpretive Description of Clusters:
The two-step cluster analysis produced a six cluster solution, which will be
described in this section. The clusters are reported in descending rank order based upon
total number of regulations comprised in each respective cluster. For example, Cluster 1
contained the largest number of regulations (19), while Cluster 6 contained the least (4).
The following cluster tables contain the specific regulation number assigned for this
study, as well as a brief paraphrased description of the actual regulation. The actual
regulation descriptions used for this study are provided in the appendix.
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Cluster 1: Highly Restrictive Regulations (29.7 Percent of Observations)
Cluster 1: Highly Restrictive Regulations
Regulation 4 – Manufacturer is prohibited from coupling services that confer a benefit to provider
Regulation 5 – Sales and marketing functions are prohibited from providing grants
Regulation 11 – Relationships with customers should not influence decisions for referrals
Regulation 15 – Compensating physicians for services related to sales and marketing activities are prohibited
Regulation 16 – Compensating physicians for time spent listening to sales presentations are prohibited
Regulation 18 – Entertainment, recreation, and travel in association with sales activities are prohibited
Regulation 19 – Gifts, gratuities, and other business courtesies are prohibited
Regulation 25 – Meals offered by sales representatives must be limited to in-office or in-hospital settings
Regulation 26 – Inclusion of a healthcare professional’s spouse or guest at a meal is prohibited
Regulation 28 – Companies are prohibited from providing any entertainment or recreational items
Regulation 32 – Financial support is prohibited for expenses of non-faculty healthcare professionals
Regulation 35 – Financial support is prohibited for healthcare professionals for professional meetings
Regulation 37 – Sponsoring companies are prohibited to influence conference content, venue or faculty
Regulation 38 – Financial support for the cost of personal expenses at conferences are prohibited
Regulation 46 – Companies are prohibited from providing recreation or entertainment at meetings
Regulation 47 – Honoraria and travel expense payments are prohibited at company sponsored meetings
Regulation 56 – Items intended for personal benefit (such as floral arrangements) is prohibited
Regulation 57 – Payments in cash or cash equivalents (such as gift certificates) are prohibited
Regulation 59 – Items designed for education of patients should only be offered on an occasional basis

Centroids
Customer Relationships
Through Communication

Cluster

1

Mean
-2.81

Std.
Deviation
.278

Core Selling
Skills
Mean
-2.82

Std.
Deviation
.230

Planning
Mean
-1.82

Std.
Deviation
.477

The "highly-restrictive regulations" group had the lowest negative scores among
the clusters and contains the largest number of regulations from the overall sample.
Nineteen of the sixty regulations studied (31.7%) were perceived as highly negative by
salespeople in each of the selling activity categories. In this group, regulations impacting
a salesperson's ability to perform "core selling skills" scored the lowest (-2.82) among all
selling activity categories. "Customer relationships through communication" activities
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scored -2.81 followed by "planning" activities at -1.82. This cluster ranks last on each
centroid and contains the largest number of observations (n=2224) of the sample.
This finding indicates that the majority of respondents studied perceive a
preponderance of regulations as negatively affecting (restricting) their ability to build
relationships through communication (relationally communicate), use their core selling
skills, and plan.

Cluster 2: No Effect Regulations (27.4 Percent of Observations)
Cluster 2: No Effect Regulations
Regulation 1 – Offer or payment of anything of value for patient referrals are prohibited
Regulation 2 – Remunerative relationships must be identified between company and
customers/speakers/consultants
Regulation 3 – Information provided to decision-makers, patients, customers must be accurate and
complete
Regulation 7 – Manufacturer must document grant making and educational presentations regularly
Regulation 8 – Any payments to cover the costs of “converting” from a competitor product is prohibited
Regulation 9 – Selective offers of remuneration is prohibited
Regulation 13 – “Switching” arrangements involving cash or other benefits are prohibited
Regulation 14 – Consulting and advisory payments must be at fair market value to bona fide consultants
or advisors for their services
Regulation 29 – Giving of any subsidy directly to a healthcare professional by a company is prohibited
Regulation 39 – Consulting agreements are prohibited to serve as either inducements or rewards for
prescribing or recommending a particular medicine or course of treatment
Regulation 41 – A legitimate need for the consulting services must be clearly identified in advance
Regulation 43 – The number of healthcare consultants retained must not exceed the number reasonably
necessary to achieve the identified purpose
Regulation 50 – Companies must establish policies for the appropriate use of speakers and their training
Regulation 52 – Speaker programs must be monitored for compliance with FDA requirements
Regulation 53 – Healthcare professionals serving as consultants, speakers, or advisors are required to
disclose the existence and nature of his/her relationship with the company
Regulation 60 – Grants, scholarships, subsidies, support, gifts, etc are prohibited as exchange for
prescribing products or for a commitment to continue prescribing products
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Centroids
Customer Relationships
Through Communication

Cluster

2

Mean
-.05

Std.
Deviation
.258

Core Selling
Skills
Mean
-.07

Std.
Deviation
.315

Planning
Mean
.10

Std.
Deviation
.388

The "no effect" cluster is the second largest group (n=2052) of observations in the
study, representing 27.4% of the sample. Unlike the other five clusters, cluster 2 contains
regulations that salespeople perceive having no effect on their selling activities. On a
seven-point Likert scale, where -3 indicated "very negatively" and +3 indicated "very
positively", this group reported sixteen of the sixty regulations (27.6%) to have little to
no effect on selling activities. "Customer relationships through communication" was
impacted the least (-.05) followed closely by "core selling skills" (-.07). The final factor,
"planning" scored slightly higher (.10), however not high enough to differentiate it from
the grouping.

In other words, cluster 2 contains regulations viewed as having neutral

impact on selling activities.

Cluster 3: Somewhat Restrictive Regulations (16.6 Percent of Observations)
Cluster 3: Somewhat Restrictive Regulations
Regulation 6 – Manufacturer is prohibited from having control over speaker or speaker content
Regulation 10 – Relationships with formulary committee members prohibited to influence decisions
Regulation 21 – Promotional materials must be consistent with approved FDA requirements and
cannot be altered, highlighted, etc.
Regulation 31 – The company is prohibited to provide any advice or guidance to CME providers
Regulation 33 – Funding is prohibited to compensate for time spent for participating in CME events
Regulation 42 – Criteria for selecting consultants must be directly related to the identified purpose
Regulation 45 – Venue and circumstances of any meeting with consultants are conducive to
consulting services and activities related to purpose of meeting; resorts are not appropriate venues
Regulation 48 – The selection or retention of speakers must be based on defined criteria
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Centroids
Customer Relationships
Through Communication

Cluster

3

Mean
-1.55

Std. Deviation
.646

Core Selling
Skills
Mean
-2.26

Std.
Deviation
.443

Planning
Mean
-1.08

Std.
Deviation
.527

This group ranked third in overall negative impact (16.6%) with 1241 overall
observations. Of the three centroids, "core selling skills" had the lowest negative score (2.26) ranking it the fourth most negative category among all groups. "Customer
relationships through communication" and "planning" scored slightly better, however
they were all perceived as negative. Cluster 3 is still relatively low on all measures and
contains eight of the sixty regulations (13%) studied. This group was most similar to
cluster 2 with respect to overall negative impact.

Cluster 4: Restrictive in Office Regulations (11.2 Percent of Observations)
Cluster 4: Restrictive in Office Regulations
Regulation 12 – Good or services provided to eliminate an expense that the physician would have
otherwise incurred is prohibited
Regulation 17 – Payments for time spent accessing web sites to view or listen to marketing
information or to perform research is prohibited
Regulation 27 – Offering “take-out” meals or meals to be eaten without a company representative
present is prohibited
Regulation 44 –The retaining company must maintain records for consulting services provided
Regulation 49 – Companies are required to “cap” the total amount of speaker compensation it will
pay annually
Regulation 55 – Promotional items such as; pens, note pads, mugs and similar “reminder” items
with company logos or product names are prohibited
Regulation 58 – Items designed for education of patients must be $100 or less in value

Centroids
Customer Relationships
Through Communication

Cluster

4

Mean
-.97

Std. Deviation
.558

Core Selling
Skills
Mean
-.59

Std.
Deviation
.527

Planning
Mean
-1.55

Std.
Deviation
.494
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This category contains two factors that were slightly negative, and equally
revealed minimal factor centroid values and rankings; "core selling skills" (-.59) and
"customer relationships through communication" (-.97). "Planning", the third factor,
reported a much more negative score (-1.55) indicating that activities such as searching
out new leads, pre-call planning, conducting targeting activities, and designing sales
plans were more negatively impacted by this group of regulations.

Cluster 5: Bad with Customer / Good in Office (8.5 Percent of Observations)
Cluster 5: Bad With Customer / Good In Office Regulations
Regulation 23 – Occasional meals may be offered, so long as the presentation provides scientific value
Regulation 30 – Financial support must be given to the CME provider directly
Regulation 34 – It is prohibited to provide meals directly at CME events, except that the CME provider may
apply the financial support from the company to provide meals for all participants
Regulation 36 – Financial support for conference registration fees must be given directly to the conference
sponsor and not to participants
Regulation 54 – Financial assistance for scholarships or other educational funds to support medical
students, residents, or fellows may not be offered directly, but may be offered to the institution

Centroids
Customer Relationships
Through Communication

Cluster

5

Mean
-2.29

Std.
Deviation
.387

Core Selling
Skills
Mean
-1.81

Std.
Deviation
.373

Planning
Mean
1.14

Std.
Deviation
.402

Examination of the fifth group (636 observations) shows that “customer
relationships through communication” and “core selling skills” were both negative (-2.29
and -1.81 respectively). “Planning” on the other hand was positive at 1.14. Cluster 5 is
unique compared to the other clusters such that no other clusters reported a mix between
positive and negative means across centroids.
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Cluster 6: Helpful Regulations (6.7 Percent of Observations)
Cluster 6: Helpful Regulations
Regulation 20 - Promotional material claims must be fair and balanced
Regulation 22 - Meals may be offered to customers and staff as long as they are modest in value
Regulation 24 – Occasional meals must be accompanied by educational or scientific presentations
Regulation 40 – Written contracts must specify the nature of consulting services to be provided

Centroids
Customer Relationships
Through Communication
Mean
Cluster

6

2.55

Std.
Deviation
.500

Core Selling Skills
Mean
2.39

Std.
Deviation
.711

Planning
Mean
2.54

Std.
Deviation
.439

This group scored the highest with respect to regulations that are perceived by
salespeople as "helpful" when performing selling activities. On a scale of -3 to +3, this
group had the highest mean score on "customer relationships through communication"
(2.55), "core selling skills" (2.39), and "planning" (2.54). This category of regulations
includes the approval of activities such as providing meals to customers and staff, the
initiation of contracts with customers to enforce agreed upon services, and requirements
of firms to substantiate product claims. Each of these regulations was perceived by
salespeople to facilitate communication with prospects, assist their interpersonal
influencing efforts, and support planning efforts. Thus, this cluster was labeled “helpful”
indicating that the majority of sales people perceived regulations 20, 22, 24, and 40 as
useful. "Helpful Regulations" is the smallest cluster representing just 6.7% of 7493 total
observations. Four of the sixty regulations included in this study reside in cluster six.
This finding indicates that less than 7 percent of the regulations examined are perceived
as "helpful" by salespeople.
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CHAPTER 5: CONCLUSION, LIMITATIONS, AND FUTURE RESEARCH
Discussion
The results of this study offer a classification system based on three selling
activity factors and six clusters or groups of regulations. Table 3 gives the mean ratings
for each taxonomic group across group descriptors. The discussion provided in the
following section is based on the results supplied by this table.

Table 3
Centroids
Customer Relationships
Through Communication
Mean
Cluster

Std. Deviation

Core Selling Skills
Mean

Planning

Std. Deviation

Mean

Std. Deviation

1

-2.81

.278

-2.82

.230

-1.82

.477

2

-.05

.258

-.07

.315

.10

.388

3

-1.55

.646

-2.26

.443

-1.08

.527

4

-.97

.558

-.59

.527

-1.55

.494

5

-2.29

.387

-1.81

.373

1.14

.402

6

2.55

.500

2.39

.711

2.54

.439

-1.24

1.539

-1.29

1.545

-.60

1.357

Combined

The results are interesting and instructive for a number of reasons. First, six
clusters of regulations were revealed which provide a foundation for understanding the
interaction between regulations and selling activities in the form of an empirical
taxonomy. This study revealed that salespeople perceive most regulations as either
highly restrictive (cluster 1), or have no effect at all (cluster 2) on their selling activities.
Very few regulations (only four out of sixty) were perceived as helpful.
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“Highly Restrictive” Regulations (cluster 1)
Respondents perceived the first cluster as the most restrictive and highly negative
group of regulations when doing their job as a salesperson. This cluster also represents
the largest number of regulations in one group (n=19), indicating an overall perception
that most regulations are viewed as highly restrictive by salespeople. A thorough
examination of the regulations within the “highly restrictive” group reveals numerous
specific examples that limit time with customers, prohibit gifts and entertainment, and
other business courtesies. This suggests that the majority of regulations enforced by the
OIG, and PhRMA may prevent customer relationship opportunities, which by default
restrict a salesperson’s ability to execute core selling skills and planning.

“No Effect Regulations” (cluster 2)
The “no effect” cluster is the second largest group containing sixteen regulations
(n=16). Examination of specific regulations linked with “no effect” show that regulations
designed to control firm level behavior, enforce federal and state laws such as antikickback legislation, and regulations governing forms of remuneration were not
perceived by salespeople as positive or negative with respect to their ability to perform
selling activities. Many of the regulations within this group are directed more toward the
firm level and show neutral or no effect on selling activities by sales representatives.
This is an interesting finding in two respects. First, this suggests that a large portion of
regulations may not be necessary considering they are viewed to have no impact on
selling activities. Second, as federal, state and local agencies continue to generate more
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regulations targeted toward sales forces, and with over 27% of existing regulations
having no effect on selling activities, a thorough needs analysis should be conducted prior
to implementation of the regulation.

“Somewhat Restrictive Regulations” (cluster 3)
Cluster three is unique such that the eight regulations (n=8) comprising this group
are largely related to third party entities which limits or eliminates the ability of a
salesperson to interact directly with their customers. For example, regulation 10
specifically states that “relationships with formulary committee members should not
include any remuneration from a manufacturer or its agents, nor to influence formulary
decisions…” In its most basic form, a “formulary” is a list of medicines that specify
which products are approved or available for physicians to prescribe. The formulary
committee is a group of advisors comprised primarily of staff physicians and pharmacists
which ultimately determine what products are placed on “formulary” (ASHP 2009).
Therefore, it is not surprising that sales representatives view these regulations as “highlyrestrictive” since they prohibit key selling activities that can influence customer buying
decisions.
In addition, many pharmaceutical firms use third-party vendors to conduct
promotional speaking events, educational symposia, and physician speaker events.
However, rules like regulation number six specifically state; “the manufacturer should
have no control over the speaker or content of an educational presentation.” This form of
regulation prohibits the sales person from speaking directly with a customer who they
have sponsored to speak. All content must go through a third-party entity. Thus, the
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salesperson is unable to build customer relationships, use his/her core selling skills, and
plan. This finding indicates that salespeople perceive certain regulations as somewhat
restrictive when dealing with entities other than their direct prospects.

“Restrictive in Office Regulations” (cluster 4)
Overall, the regulations grouped in the “restrictive in office” cluster (n=7) are all
perceived to have a negative impact on selling activities. However, unlike the “no effect”
cluster which was highly negative in all categories, this cluster was slightly negative in
customer relationships through communication, and core selling skills. On the other
hand, planning was ranked highly negative in this category. Inspection of the seven
regulations linked with the “restrictive in office” cluster suggests that planning activities
are perhaps more strategic and therefore experience a greater negative impact than other
more direct customer activities such as relationship building and core selling skills.
Historically, giving inexpensive “reminder” promotional items (pens, note pads,
mugs, etc. with company logos or product names) to potential and existing customers was
a common selling activity for pharmaceutical representatives. This practice was believed
to enhance a sales person’s ability to “gain access” to new customers, search out new
leads, and conduct targeting activities. For example, experienced sales people would use
a coffee mug that contained their product name and logo as a way to get a customer’s
attention and to initiate product or service discussions.
Regulation 55, cluster 4, currently prohibits the practice of providing items for
healthcare professionals’ use that do not advance disease or treatment education,
consequently the salesperson perceives this regulation as “highly restrictive” when

59
conducting planning activities such as pre-call planning, and searching out new leads.
However, it was perceived to have minimal negative effect on activities such as listening
to customers or handling customer objections. This discovery demonstrates the different
effects a regulation can have depending on the specific selling activity being conducted.

“Bad with Customer / Good in Office Regulations” (cluster 5)
The “bad with customer / good in office” cluster (n=5) produced a unique
distinction suggesting this group of regulations has an opposite effect on selling activities
conducted in front of customers ("customer relationships through communication" and
"core selling skills", -2.29 and -1.81 respectively) versus those conducted away from
customers (“planning”, 1.14). Inspection of the five regulations in the “bad with
customer / good in office” cluster reveals that four of the regulations (regulations 30, 34,
36, and 54) limit and/or prohibit providing meals, financial support, or other business
courtesies unless it is facilitated through a third-party entity such as conference sponsors,
event planners, or academic or training institutions. In addition, regulation 23 states;
“occasional meals may be offered as a business courtesy to healthcare professionals
(including members of their staff) attending sales/marketing presentations as long as the
presentations provide scientific or educational value”.
Each of the regulations in “bad with customer / good in office” contain a
“condition” statement (i.e., as long as; only if; or except that) that appears to separate
selling activities conducted in the customer’s presence (“customer relationships through
communication" and "core selling skills") from those conducted away from customers
(“planning”). The existence of the “condition” statements appear to have opposite effects
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on selling activities that are conducted while face-to-face with customers versus those
conducted outside the presence of a customer. This finding, the fact that certain
regulations can have both positive and negative effects on selling activities, further
supports the value of a classification system such as the taxonomy presented here.

“Helpful Regulations” (cluster 6)
After examining the four regulations (n=4) found within the “helpful” group, we
observed that each of the regulations supported activities such as providing customers
with occasional meals, the ability to include staff members in the activity, and the
requirement that customers must sign a contract describing the nature of their
commitment and services to be provided. If a regulation makes it easy to gain access to a
customer, and facilitates relationship building such as providing a meal, it is not
surprising that sales representatives would find these regulations as “helpful”. What this
suggests is that sales organizations may benefit by providing their salespeople with
regulations describing what they "can" do rather than what they "cannot" do. Each of the
four regulations within this group specifically states examples of promotional activities
that are allowed. Of note, these are the only four regulations that describe what is
allowed versus what is prohibited. The usefulness of these regulations was viewed as
positive by all respondents indicating a wide acceptance among the entire sales force.

Taxonomy in Research
This article defines the process and reports the findings of a comprehensive
taxonomy development effort, based on how regulations affect selling activities. The
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basis of the entire project, however, is that sales forces continue to spend billions of
dollars annually to support thousands of direct salespeople and their activities, without
any understanding of the interrelated phenomena that regulations impose on selling
activities. Clearly, the growing number of regulations placed upon sales forces indicates
a critical transformation in the business setting that affects the discipline of selling and
sales management. Taxonomies are consistently used in business research and are
fundamental in classifying and learning about phenomena. Until now, conceptualization
of how regulations affect selling activities has not been empirically studied. The results
of this study and the taxonomy presented here offer numerous insights into organizing
complex sets of regulations and selling activities.
The taxonomy produced in this study is based on three (3) factors and six (6)
clusters or groups. Of particular interest, the results of the factor analysis revealed three
distinct groups of selling activities; (1) customer relationships through communication,
(2) core selling skills, and (3) planning. They seemingly resemble the sales
communication behaviors measures (“get”, “give”, and “use”) adapted from Reid,
Minton, and Plank (1996), however by examining the selling activities in the presence of
regulations, our factor analysis effectually combined “questioning”, “listening”,
“charismatic presentations”, and “working well with people” into its own category
renamed “customer relationships through communication”. The second new group
(factor) that was identified includes a combination of “customer participation”, “getting
customers to see product benefits”, “meeting customer needs”, and “ability to handle
objections”. This new category represents “core selling skills” that engage customers in
the buying process. Finally, the last category (“planning”) grouped items that involved
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activities conducted away from customers such as “pre-call planning”, “designing a sales
plan”, and “conducting targeting activities”. From a selling perspective, it is quite
interesting to learn that the presence of regulations changed the sales communication
behavior categories into different groupings effectually describing new categories of
selling activities.
The taxonomy of regulations presented herein provides a fascinating picture of
the impact they can have on selling activities. Although much has been written about the
existence of regulations in business, our study is the first to specifically investigate and
supply strong support through an empirically derived taxonomy how certain regulations
affect some selling activities more than others. One of our key findings indicates that the
perceived effects of regulations are very “cleanly” loaded into respective categories
(clusters) by respondents. In other words, there is a very high degree of homogeneity
within clusters. For example, regulations that prohibit gift giving, entertainment,
business courtesies, and other relationship building activities loaded exclusively into the
“highly restrictive” (very negative) cluster of regulations by all respondents with no
respondent ratings found in other clusters. The same high degree of homogeneity was
observed in the “helpful” (very positive) cluster of regulations whereby all respondents
perceived the ability to “provide meals to customers”, “provide meals to staff”, and
“written contracts with customers” as positively affecting their ability to do their job as a
sales person. This finding suggests that pharmaceutical representatives are very clear and
consistent regarding how regulations affect their selling activities. This could be a
reflection of the level of regulatory training they receive or possibly the clear explicit
nature of how the regulations are written, obviously a fertile area for future research.
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By using these categories, future researchers can add generalizability to their
findings on the impact of regulations allowing comparisons across industries, regulating
entities, and regulations themselves. It is hoped that the tool created here will spur
research into the interaction between regulation and sales.

Managerial Implications
In terms of practical application, the taxonomy developed is this study could help
a manager develop their own companies’ approach to regulations and ascertain the
impact different regulations have on their sales force activities. Furthermore, the value in
our taxonomy lies in its potential to provide managerial insight and direction by isolating
groups of regulations with predictive significance regardless of industry.
Sales managers whose industries are exploring the idea of tighter regulatory
controls, or whose firms have not considered the impact regulations might have on their
sales and marketing activities, can use this taxonomy to develop alternative selling
strategies to enhance customer impact. For example, by identifying whether salespeople
perceive a regulation as “highly restrictive”, “helpful”, or having “no effect” on their dayto-day activities, a manager can tailor training and education for his/her sales force in
order to provide the skills necessary to better serve their customers as well as comply
with the regulation(s).
From a marketing perspective, using the known clusters of regulations,
practitioners can verify whether the promotional materials and activities they believe are
vital to their sales team fit into one of the six clusters, or not. Based on the cluster,
marketing managers should consider whether or not they want to produce particular
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resources and supplies, or develop different strategies to accommodate the growing
number of regulations with which they must comply. In other words, are there certain
strategies that allow them to overcome issues related to regulations and their selling
activities better than others?
For the sales manager, this study may be useful in the identification of skills and
behaviors associated with highly effective sales representatives in a highly regulated
environment. For example, a successful pharmaceutical representative that relies heavily
on building customer relationships through communication as their primary selling skill
may find the regulation that permits occasional meals at meetings, so long as the
presentation provides scientific value, as highly restrictive. From their perspective, they
prefer to have lunch with a customer to build relationships and rapport and believe that
conducting a scientific presentation would negatively impact their interaction. Therefore,
they may decide to not provide occasional meals at all and exclude customers that will
only meet over lunch. On the other hand, another successful pharmaceutical
representative has found that conducting scientific presentations at lunch meetings is an
effective way to search out new leads, target customers, and design their sales plan. For
those reasons, the second representative routinely meets new customers over lunch
meetings while sharing scientific product information. This example implies the need for
further training among affected sales representatives and managers based upon identified
best practices.
Finally, from the taxonomy developed in this study, managers can sort their own
companies’ regulations on the basis of the classification scheme presented. From the
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taxonomy, they can determine new ways to approach customers and develop alternative
selling strategies.

Limitations and Future Research Opportunities
Before future research opportunities are noted, several limitations should be
raised. First, the sample in this study included sales representatives from one firm within
the pharmaceutical industry. Although pharmaceuticals is known to be one of the most
regulated industries today, industries such as banking, real estate, telecommunications,
and tobacco would also be appealing and meaningful for other investigators to test our
taxonomical methodology. We acknowledge this as a "limitation", however this was a
mindful strategic choice in designing the research.
An inherent limitation of the taxonomic process includes several subjective and
sequential decisions related to data analysis. We recognize that strong conceptual
support is necessary to deal with issues such as what variables to include, why groups
exist in the first place, and determining the number of clusters in the final solution.
Additionally, analysis of this type of data required several different analytical
approaches; however the present study relies heavily on the use of exploratory factor
analysis (EFA), and two-step cluster analysis. Though each step of the analysis was
carefully specified and reviewed by two additional researchers, applying a different
sequence of analytical steps might deduce the data in a slightly different way. We
recognize that problems are inherent in both methods which is acknowledged.
Future research directions are several. Marketing and sales scholars can play an
important role in the growing area of regulations and selling. To date, key decisions
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about how to effectively sell in an ever increasing regulated environment have been
guided by “reaction” and “intuition” rather than by marketing/sales experts and scholars.
Research in the area of sales strategy development is needed to guide these decisions
which often have huge financial consequences. Building upon an initial taxonomical
scheme, as described here, can help develop theoretical strategy frameworks for future
research in the areas of relational communication, and interpersonal influencing in the
context of selling. Moreover, further research could explore which regulations impact
customer commitment and trust (Morgan and Hunt 1994).
There is a pressing need for better understanding of the costs associated with
regulations placed on sales organizations. Many companies are unaware of the costs to
monitor, enforce, and implement regulations within their organizations and how those
costs impact overall firm performance. It would be interesting to extend this regulatory
taxonomy to include demographic data, longitudinal performance outcomes, and cost
measures. With large quantities of complex and vague regulations with which sales
people must comply, our research underscores the need to execute fiscal analyses on the
major clusters of regulations to examine whether a regulation’s intended benefits surpass
its costs. The research presented here provide a timely context for further research on the
interaction between regulations and selling behaviors, which seem to be central to the
advancement in research selling and sales management.
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APPENDIX 1

Complete Typology for Source of Regulations
Federal Regulations
1. Office of Inspector General (OIG)
2. Federal Trade Commission (FTC)
3. Division of Drug Marketing and Communication (DDMAC)

State Regulations (including District of Columbia)
1. Massachusetts
2. California
3. D.C.

4. Maine
5. Vermont
6. South Dakota

7. Nevada

Industry Regulations
Pharmaceutical Research and Manufacturers of America (PhRMA)

Firm Self-Regulations
6 major pharmaceutical firms will be used in the study. Names are blinded to the reader to
honor requested anonymity by the firms.
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APPENDIX 2
Comprehensive list of the 94 “core” regulations
ID
1

2

3

4

5

6

7

8

9

Guideline / Regulation
Pharmaceutical manufacturers must develop and distribute
written standards of conduct, as well as written policies,
procedures and protocols that verbalize the company’s
commitment to compliance.
Pharmaceutical manufacturers must include adherence to
the compliance program as an element in evaluating
management and employees.
Pharmaceutical manufacturers must address specific areas
of potential fraud and abuse, such as the reporting of
pricing and rebate information to the federal health care
programs, and sales and marketing practices, within their
policies and procedures.
Pharmaceutical manufacturers must designate a
compliance officer other appropriate bodies (e.g., a
corporate compliance committee) charged with the
responsibility for developing, operating, and monitoring the
compliance program, and with authority to report directly to
the board of directors and/or the president or CEO.
Pharmaceutical manufacturers must develop and
implement regular, effective education and training
programs for all affected employees.
Pharmaceutical manufacturers must create and maintain an
effective line of communication between the compliance
officer and all employees.
Pharmaceutical manufacturers must develop a process
(such as a hotline or other reporting system) to receive
complaints or questions.
Pharmaceutical manufacturers must adopt procedures to
protect the anonymity of complaints and to protect
“whistleblowers” from retaliation.
Pharmaceutical manufacturers must use audits and/or other
risk evaluation techniques to monitor compliance, identify
problem areas, and assist in the reduction of identified
problems.
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10

11

12

13

14

15

16

17

18

19

Pharmaceutical manufacturers must develop policies and
procedures for addressing the non-employment or retention
of individuals or entities excluded from participation in
federal health care programs.
Pharmaceutical manufacturers must enforce appropriate
disciplinary action against employees or contractors who
have violated company policies and procedures and/or
applicable federal health care program requirements.
Pharmaceutical manufacturers must develop policies and
procedures for the investigation of identified instances of
noncompliance or misconduct.
Policies and procedures for the investigation of identified
instances of noncompliance or misconduct must include
directions regarding the prompt and proper response to
detected offenses, such as the initiation of appropriate
corrective action and preventive measures and processes
to report the offense to relevant authorities in appropriate
circumstances.
Every pharmaceutical manufacturer is required to develop
and distribute written compliance standards, procedures,
and practices that guide the company and the conduct of its
employees in day-to-day operations.
Policies and procedures that guide the company and the
conduct of its employees in day-to-day operations must be
developed under the direction and supervision of the
compliance officer, the compliance committee, and
operational managers.
At a minimum, the policies and procedures must be
provided to all employees who are affected by these
policies, and to any agents or contractors who may furnish
services that impact federal health care programs (e.g.,
contractors involved in the co-promotion of a
manufacturer’s products.
Pharmaceutical manufacturers must develop a general
corporate statement of ethical and compliance principles
that will guide the company’s operations.
Pharmaceutical manufacturers must develop of code of
conduct statement of principles to include the company’s
expectations of commitment to compliance by
management, employees, and agents, and should
summarize broad ethical and legal principles under which
the company must operate.
Pharmaceutical manufacturers must include their board of
directors, CEO, president, members of senior management,
and other personnel from various levels of the
organizational structure in the development of all aspects of
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20

21

22

23
24

25

26

27

28

29

30

31

32

the compliance program, especially the code of conduct.
Pharmaceutical manufacturers are responsible for ensuring
the integrity of data they generate that is used for
government reimbursement purposes.
Pharmaceutical manufacturers are prohibited to offer
payments (in any form, whether the payments are direct or
indirect) purposefully to induce or reward the referral or
generation of federal health care business. (Anti-kickback
statute)
Pharmaceutical manufacturers are prohibited to offer
anything of value in return for purchasing, leasing, ordering,
or arranging for or recommending the purchase, lease, or
ordering of any item or service reimbursable in whole or
part by a federal health care program.
Pharmaceutical manufacturers are prohibited to solicit or
accept remuneration for referrals.
Pharmaceutical manufacturers must identify any
remunerative relationship between itself (or its
representatives) and persons or entities in a position to
generate federal health care business for the manufacturer
directly or indirectly.
Pharmaceutical manufacturers are prohibited from
arrangements or practices that have a potential to interfere
with, or skew, clinical decision-making.
Pharmaceutical manufacturers are prohibited from
arrangements or practices that have a potential to
undermine the clinical integrity of a formulary process.
Pharmaceutical manufacturers are prohibited from
arrangements or practices that involve providing information
to decision-makers, prescribers, or patients that does not
include complete and accurate information (not misleading).
Pharmaceutical manufacturers are prohibited from
arrangements or practices that have a potential to increase
costs to the federal health care programs, beneficiaries, or
enrollees.
Pharmaceutical manufacturers are prohibited from
arrangements or practices that have the potential to be a
disguised discount to circumvent the Medicaid Rebate
Program Best Price calculation.
Pharmaceutical manufacturers are prohibited from
arrangements or practices that have a potential to increase
the risk of overutilization or inappropriate utilization.
Pharmaceutical manufacturers are prohibited from
arrangements or practices that raise patient safety or
quality of care concerns.
Pharmaceutical manufacturers are prohibited from
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33

34

35

36

37
38

39

40

41
42

43

44

45

providing any remuneration to a direct purchaser (e.g.,
hospitals, nursing homes, pharmacies, some physicians),
as well as indirect purchasers (e.g., health plans) that is
expressly or impliedly related to a sale.
Pharmaceutical manufacturers are prohibited from hiding
de facto pricing concessions to other purchasers to avoid
passing on the same discount to others.
Pharmaceutical manufacturers are prohibited from offering
services that have no substantial independent value to the
purchaser (e.g., billing assistance tailored to the purchase
products, reimbursement consultation, and other programs
specifically tied to support of the purchased product).
Pharmaceutical manufacturers are prohibited from offering
funding (grants) that are conditioned, in whole or in part, on
the purchase of products.
Pharmaceutical manufacturers are prohibited from
influencing the substance of an educational program or the
presenter.
Pharmaceutical manufacturers must separate their grant
making functions from their sales and marketing functions.
Third-party scientific and educational conferences or
professional meetings are permitted provided; (a) the
gathering is primarily dedicated, in both time and effort, to
promoting objective scientific and educational activities and
discourse, (b) the main incentive for bringing attendees
together is to further their knowledge on the topic(s) being
presented.
The pharmaceutical manufacturer should have no control
over the speaker or content of any educational
presentation.
Items intended for the personal benefit of healthcare
professionals (such as floral arrangements, artwork, music
CDs or tickets to a sporting event) are prohibited.
Payments in cash or cash equivalents (such as gift
certificates) are prohibited.
Pharmaceutical manufacturers are prohibited from offering
payments to cover the costs of “converting” from a
competitor’s product.
Pharmaceutical manufacturers are prohibited from
providing selective offers of remuneration (i.e., offers made
to some but not all purchasers).
Pharmaceutical manufacturers are prohibited from offering
any remuneration directly or indirectly to person(s) in a
position to influence formulary decisions related to the
manufacturer’s products.
Pharmaceutical manufacturers are prohibited from offering
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46

47

48

49

50

51

52

53

54
55

56
57

lump sum payments for inclusion in a formulary or for
exclusive or restricted formulary status.
Pharmaceutical manufacturers are prohibited from
providing anything of value to a physician who might
prescribe the manufacturer’s product.
Pharmaceutical manufacturers are prohibited from
providing switching arrangements that involve offering
physicians cash payments or other benefits each time a
patient’s prescription is changed to the manufacturer’s
product from a competing product.
Pharmaceutical manufacturers are prohibited from
compensating physicians as “consultants” when they are
expected to attend meetings or conferences primarily in a
passive capacity.
Pharmaceutical manufacturers are prohibited from
compensating physicians for services connected directly or
indirectly to a manufacturer’s marketing and sales activities,
such as speaking, certain research, or preceptor or
“shadowing” services.
Providing items for healthcare professional’ use that do not
advance disease or treatment education, even if they are
practice-related items of minimal value (such as pens, note
pads, mugs and similar “reminder” items with company or
product logos) are prohibited.
Pharmaceutical manufacturers are prohibited from
compensating physicians for time spent listening to sales
representatives market pharmaceutical products.
Pharmaceutical manufacturers are prohibited from
compensating physicians for time spent accessing web
sites to view or listen to marketing information or perform
“research”.
Pharmaceutical manufacturers are prohibited from
providing entertainment, recreation, travel, meals, or other
benefits in association with information or marketing
presentations.
Pharmaceutical manufacturers are prohibited from offering
gifts, gratuities, and other business courtesies.
Pharmaceutical manufacturers and their representatives
are prohibited from using activities that channel improper
remuneration to physicians or others in position to generate
business for the manufacturer or to influence or control the
content of a program.
Modest, occasional meals are permitted as long as they are
offered in the appropriate circumstances and venues.
Companies are required to separate its CME grant-making
functions from its sales and marketing departments.
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58

59

60

61

62

63
64

65

66

67

68

69

70

Pharmaceutical manufacturers are required to institute and
implement corrective action and disciplinary policies
applicable to sales agents who engage in improper
marketing.
Pharmaceutical manufacturers are required to avail itself of
the advisory opinion process if it has questions about
particular practices used by its sales force.
Pharmaceutical manufacturers are required to establish an
effective system for tracking, compiling, and reviewing
information about sales force activities, including if
appropriate, random spot checking.
Pharmaceutical manufacturers are required to provide
accurate and not misleading promotional materials when
interacting with healthcare professionals.
Promotional materials provided to healthcare professionals
must only make claims about a product when properly
substantiated.
Promotional materials provided to healthcare professionals
must reflect the balance between risks and benefits.
Companies are prohibited from providing meals directly at
CME events, except that a CME provider at its own
discretion may apply the financial support provided by a
company for a CME event to provide meals for all
participants.
Any meals offered in connection with informational
presentations made by field sales representatives or their
immediate managers should also be limited to in-office or
in-hospital settings.
Inclusion of a healthcare professional’s spouse or other
guest in a meal accompanying an informational
presentation made by or on behalf of a company is
prohibited.
It is prohibited for companies or agents of the companies to
provide entertainment or recreational items, such as tickets
to the theater or sporting events, sporting equipment, or
leisure or vacation trips, to any healthcare professional who
in not a salaried employee of the company.
It is required that companies adopt a Comprehensive
Compliance Program (CCP) that is in accordance with both
the OIG Guidance and the most recent version of the
PhRMA Code.
Pharmaceutical companies are required to annually set a
spend limit on gift s and
meals to California HCPs and publicly post that limit, along
with a copy of its CCP and certification of compliance.
Manufacturers and wholesalers who employ a person to
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71

72
73

74

75

76

77

78
79

80

81
82
83
84
85

sell or market a drug, medicine, chemical, device or
appliance in the state must file annual submissions with the
Nevada Board of Pharmacy confirming compliance with the
law’s training, investigation and auditing requirements.
The law requires manufacturers and wholesalers to adopt a
Marketing Code of Conduct setting forth the company’s
“practices and standards that govern the marketing and
sale of its products.
Companies are required to disclose the value, nature and
purpose of gift s provided to HCPs
Requires companies to adopt and certify compliance with
the Massachusetts Department of Health’s Marketing Code
of Conduct provisions.
limits the ability of PBMs to switch South Dakota residents’
prescription drugs by allowing higher-priced drugs to be
substituted for lower-priced prescribed drugs only for
medical reasons that benefit the covered individual
Sales representatives are required to obtain a license to
“practice pharmaceutical detailing” in the District while
certifying compliance with a marketing code of ethics.
Sales representatives who interact with District of Columbia
HCPs must keep detailed records about those interactions.
These records include not only the contact information for
the HCP or the employee or representative of the HCP, but
also details about the types of promotional materials left
with the individual and whether any sample products were
provided.
Reporting of expenses related to company-sponsored
educational and informational sessions, including food,
entertainment, travel, gifts valued at $25 or more.
The provision of gifts by pharmaceutical and medical device
manufacturers to healthcare professionals is prohibited.
All sales and marketing employees are required to
successfully pass the company developed pharmaceutical
promotional guidelines exam.
All sales and marketing employees are prohibited to
participate in customer meetings when a scientific manager
(liaison) is present.
Sales representatives must receive prior approval from their
immediate supervisor for all promotional expenditures.
It is prohibited for sales representatives to “steer” physician
speaker content or presentation materials.
All speaker events are prohibited.
Providing entertainment, meals, and gifts is prohibited by all
sales and marketing personnel.
Sales representatives are prohibited from attending
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92
93
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scientific/educational meetings conducted by medical affairs
or scientific liaisons.
Sales representatives are prohibited from altering
promotional materials in any way (e.g., using yellow
highlighters, circling certain items of interest, etc.).
Sales representatives are prohibited to use any “nonapproved” promotional information items (e.g., books,
newspaper articles, articles printed from the web, etc.)
Sales representatives must provide an approved
promotional proof source at every customer interaction.
Sales representatives are prohibited from offering “takeout” meals to customers.
Sales representatives are prohibited from responding to
customer questions not related to their own product (e.g.,
competitive product questions).
Sales representatives are prohibited to discuss nonapproved (FDA) indications for their products. Even if
asked by the physician.
Sales representatives are prohibited from using competitive
product package inserts to make product comparisons.
If a sales representatives is a currently licensed medical
professional (e.g., R.N., Paramedic, M.D., etc.) it is
prohibited to exercise the skills by which you are licensed
while actively working for the company. In other words, it is
prohibited to offer medical advice, care, etc. while working
as a representative of the company.
Sales representatives are prohibited from participating in
“preceptorships” or “shadowing” events with physicians or
other medical professionals.
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APPENDIX 3

REGULATIONS:
OFFICE OF INSPECTOR GENERAL (OIG), HHS;
THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF
AMERICA (PhRMA)
===============================================================
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency: Office of Inspector General (OIG), HHS
OIG Compliance Program Guidance for Pharmaceutical Manufacturers
Background
Preventing and reducing fraud and abuse in federal health care programs is a major
initiative of the OIG (Federal Register 2003). The OIG states (2003, p. 23731), “The
purpose of the compliance program guidance is to encourage the use of internal controls
to efficiently monitor adherence to applicable statutes, regulations and program
requirements.”

Guidelines/ regulations for pharmaceutical manufacturers:
A. Title: The Basic Compliance Elements
a. The development and distribution of written standards of conduct, written
policies, procedures and protocols that verbalize the company’s commitment to
compliance.
b. Designation of a compliance officer.
c. Development and implementation of regular, effective education and training
programs.
d. The creation and maintenance of an effective line of communication between the
compliance officer and all employees.
e. The use of audits and/ or other risk evaluation techniques to monitor compliance.
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f.

The development of policies and procedures for the investigation of identified
instances of noncompliance or misconduct.

B. Title: Integrity of Data Used to Establish or Determine Government Reimbursement

Description: “Many federal and state health care programs establish or ultimately
determine reimbursement rates for pharmaceuticals, either prospectively or
retrospectively, using price and sales data directly or indirectly furnished by
pharmaceutical manufacturers. The government sets reimbursement with the
expectation that the data provided are complete and accurate.”
Guideline: The knowing submission of false, fraudulent, or misleading
information is actionable. Under the False Claims Act, a pharmaceutical
manufacturer may be liable if government reimbursement information is not
reported completely and accurately. Manufacturers’ reported prices should
accurately take into account price reductions, cash discounts, free goods
contingent on a purchase agreement, rebates, up-front payment, coupons goods in
kind, free or reduced-price services, grants, or other price concessions or similar
benefits offered to some or all purchases.
Guideline summary: Pharmaceutical manufacturers are responsible for ensuring
the integrity of data they generate that is used for government reimbursement
purposes.
C. Title: Kickbacks and Other Illegal Remuneration

Description: “The anti-kickback stature is a criminal prohibition against
payments (in any form, whether the payments are direct or indirect) made
purposefully to induce or reward the referral or generation of federal health care
business.”
Guideline: The offer or payment of anything of value for patient referrals, but
also the offer or payment of anything of value in return for purchasing, leasing,
ordering, or arranging for or recommending the purchase, lease, or ordering of
any item or service reimbursable in whole or part by a federal health care
program, is prohibited.
Guideline summary: A manufacturer should identify any remunerative
relationship between itself (and its representatives) and persons or entities in a
position to generate federal health care business for the manufacturer directly or
indirectly.
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i. The arrangement or practice shall not have a potential to interfere with,
or skew, clinical decision-making.
ii. The arrangement or practice shall not undermine the clinical integrity of
a formulary process.
iii. If the arrangement or practice involves providing information to
decision-makers, prescribers, or patients, the information must be
complete, accurate and not misleading.
iv. The arrangement or practice shall not have a potential to increase costs
to the federal health care programs, beneficiaries, or enrollees.
v. The arrangement or practice shall not have the potential to be disguised
as a discount to circumvent the Medicaid Rebate Program Best Price
calculation.
vi. The arrangement or practice shall not have a potential to increase the
risk of overutilization or inappropriate utilization.
vii. The arrangement or practice shall not raise patient safety or quality of
care concerns.
D. Title: Relationships with Purchases and their agents

Description: “Pharmaceutical manufacturers offer purchasers a variety of price
concessions and other remuneration to induce the purchase of their products.
Inducements offered to purchasers potentially implicate the anti-kickback stature
if the purchased products are reimbursable to the purchase, in whole or in part,
directly or indirectly, by any of the federal health care programs. Any
remuneration from a manufacturer provided to a purchaser that is expressly or
impliedly related to a sale potentially implicates the anti-kickback stature and
should be carefully reviewed.”
Guidelines:
i. Product Support Services: A manufacturer is prohibited, under the antikickback statute, from coupling a service that has no independent value in
tandem with another service or program that confers a benefit on a
referring provider. “For example, the anti-kickback stature would be
implicated if a manufacturer were to couple a reimbursement support
service with a promise that a purchaser will pay for ordered products only
if the purchase is reimbursed by a federal health care program.”
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ii. Educational Grants: Pharmaceutical manufacturers sometimes provide
grant funding for a wide range of educational activities. Funding that is
conditioned, in whole or in part, on the purchase of product implicates the
statute, even if the educational or research purpose is legitimate.
Therefore, to reduce the risks that a grant program is used improperly to
induce or reward product purchases or to market product inappropriately,
manufacturers should separate their grant making functions from their
sales and marketing functions. Sales and marketing functions are
prohibited from providing grants.
Manufacturers must establish objective criteria for making grants that do
not take into account the volume or value of purchases made by, or
anticipated from, the grant recipient.
The manufacturer should have no control over the speaker or content of
the educational presentation.
Compliance with such procedures should be documented and regularly
monitored.
iii. Research Funding: Manufacturers often contract with purchasers of
their products to conduct research activities on behalf of the manufacturer
on a fee-for-service basis. Manufacturers should develop contracting
procedures that clearly separate the awarding of research contracts from
marketing.
iv. Other remuneration to purchasers: Any remuneration from a
manufacturer provided to a purchaser that is expressly or impliedly related
to a sale may implicate the anti-kickback stature and should be carefully
reviewed.
a. Any payments to cover the costs of “converting” from a
competitor’s product are prohibited.
b. Selective offers of remuneration (i.e., offers made to some but
not all purchasers) may increase potential risk if the selection
criteria relate directly or indirectly to the volume or value of
business generate, are therefore prohibited.
c. Relationships with formulary committee members should not
include any remuneration from a manufacturer or its agents
directly or indirectly to person in position to influence formulary
decisions.
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d. Formulary placement payments for inclusion in a formulary or
for exclusive or restricted formulary status are prohibited.
e. Relationships with physicians and other persons and entities in a
position to make or influence referrals should not influence the
referral, ordering, or prescribing of the manufacturers’’ products.
f. If goods or services provided by the manufacturer eliminate an
expense that the physician would have otherwise incurred (i.e.,
have independent value to the physician), or if items or services are
sold to a physician at less than their fair market value, the
arrangement is prohibited.
g. “Switching” arrangements involve pharmaceutical
manufacturers offering physicians or others cash payments or other
benefits each time a patient’s prescription is changed to the
manufacturer’s product from a competing product, is prohibited.
h. Consulting and advisory payments whereby pharmaceutical
manufacturers frequently engage physicians and other health care
professionals to furnish personal services as consultants or advisers
to the manufactures must be at fair market value to small numbers
of physicians for bona fide consulting or advisory services.
i. Compensating physicians for services directly or indirectly
related to sales and marketing activities such as speaking, certain
research, or preceptor or “shadowing” services is prohibited.
j. Payments for detailing (i.e., compensating physicians for time
spent listening to sales representatives market pharmaceutical
products), is prohibited.
k. Payments for time spent accessing web sites to view or listen to
marketing information or perform “research” is prohibited.

v. Business courtesies and Other Gratuities: Pharmaceutical companies
and their employees and agents often engage in a number of others
arrangements that offer benefits, directly or indirectly, to physicians or
others in a position to make or influence referrals.
a. Entertainment, recreation, travel, meals, or other benefits in
association with information or marketing presentations should be
avoided.
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b. Gifts, gratuities, and other business courtesies should be
avoided.
===============================================================

THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
(PhRMA)
Code on Interactions with Healthcare Professionals
Background
The Pharmaceutical Manufacturers Association was founded in 1958. Its name was
changed to the Pharmaceutical Research and Manufacturers of America in 1994.
“Ethical relationships with healthcare professionals are critical to our mission of helping
patients by developing and marketing new medicines. This document focuses on
interactions with healthcare professionals that relate to the marketing of products. This
Code is to reinforce our intention that our interactions with healthcare professionals are
professional exchanges designed to benefit patients and to enhance the practice of
medicine.”

Code/ guidelines/ regulations for pharmaceutical manufacturers:
1. “Basis of Interactions: Promotional materials provided to healthcare professionals by or
on behalf of a company should: (a) be accurate and not misleading; (b) make claims
about a product only when properly substantiated; (c) reflect the balance between risks
and benefits; and (d) be consistent with all other Food and Drug Administration (FDA)
requirements governing such communications.”
2. Informational Presentations by Pharmaceutical Company Representatives and
Accompanying Meals
a. It is appropriate for occasional meals to be offered as a business courtesy to the
healthcare professionals as well as members of their staff attending presentations,
so long as the presentations provide scientific or education value and the meals
(a) are modest as judged by local standards; (b) are not part of an entertainment
or recreational event; and (c) are provided in a manner conducive to
informational communication.
b. Any such meals offered in connection with informational presentations made by
field sales representatives or their immediate managers should also be limited to
in-office or in-hospital settings.
c. Inclusion of a healthcare professional’s spouse or other guest in a meal
accompanying an informational presentation made by or on behalf of a company
is not appropriate.
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d. Offering “take-out” meals or meals to be eaten without a company representative
being present in not appropriate.
3. Prohibition on Entertainment and Recreation
a. Companies should not provide any entertainment or recreational items.
i. Examples include but not limited to: tickets to the theater or sporting
events, sporting equipment, or leisure or vacation trips.
ii. Such entertainment or recreational benefits should not be offered,
regardless of (1) the value of the items; (2) whether the company engages
the healthcare professional as a speaker or consultant, or (3) whether the
entertainment or recreation is secondary to an educational purpose.
4. Pharmaceutical Company Support for Continuing Medical Education
a. Giving of any subsidy directly to a healthcare professional by a company is
prohibited.
b. Any financial support should be given to the CME provider, which, in turn, can
use the money to reduce the overall CME registration fee for all participants.
c. The company is prohibited to provide any advice or guidance to the CME
provider, even if asked by the provider, regarding the content or faculty for a
particularly CME program funded by the company.
d. Financial support is prohibited for the costs of travel, lodging, or other personal
expenses of non-faculty healthcare professionals attending CME.
e. Funding should not be offered to compensate for the time spent by healthcare
professionals participating in the CME event.
f. A company should not provide meals directly at CME events, except that a CME
provider at its own discretion may apply the financial support provided by a
company for CME event to provide meals for all participants.
5. Pharmaceutical Company Support for Third-Party Educational or Professional Meetings
a. Any subsidy or financial support for professional meetings may not be provided
to a healthcare professional.
b. Financial support for professional meetings should be given directly to the
conference’s sponsor, which, in turn, can use the money to reduce the overall
conference registration fee for all attendees.
c. When companies underwrite medical conferences or meetings other than their
own, responsibility for and control over the selection of content, faculty,
educational methods, materials, and venue belongs to the organizers of the
conference and may not be influence by the sponsoring company.
d. Financial support for the costs of travel, lodging, or other personal expenses is
prohibited.
6. Consultants
a. Consulting agreements are prohibited to serve as either inducements or rewards
for prescribing or recommending a particular medicine or course of treatment.
b. A written contract must specify the nature of the consulting services to be
provided and the basis for payment of those services.
c. A legitimate need for the consulting services must be clearly identified in
advance of requesting the services and entering into arrangements with the
prospective consultants.
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d. The criteria for selecting consultants must be directly related to the identified
purpose and the persons responsible for selecting the consultants have the
expertise necessary to evaluate whether the particular healthcare professionals
meet those criteria.
e. It is required that the number of healthcare professionals retained is not greater
than the number reasonably necessary to achieve the identified purpose.
f. The retaining company must maintain records concerning and makes appropriate
use of the services provided by consultants.
g. The venue and circumstances of any meeting with consultants are conducive to
the consulting services and activities related to the services are the primary focus
of the meeting; specifically, resorts are not appropriate venues.
h. Companies are prohibited to provide recreational or entertainment events in
conjunction with consultant/ educational meetings.
i. It is prohibited to pay honoraria or travel or lodging expenses to non-faculty and
non-consultant healthcare professional attendees at company-sponsored
meetings, including attendees who participate in interactive sessions.
7. Speaker Programs and Speaker Training Meetings
a. Company decisions regarding the selection or retention of healthcare
professionals as speakers should be made based on defined criteria such as
general medical expertise and reputation.
b. Each company should cap the total amount of annual compensation it will pay to
an individual healthcare professional in connection with all speaking
arrangements.
c. Each company should develop policies addressing the appropriate use of
speakers, including utilization of speakers after training and the appropriate
number of engagements for any particular speaker over time.
d. Speakers and their materials must clearly identify the company that is sponsoring
the presentation.
e. Companies must monitor speaker programs for compliance with FDA regulatory
requirements for communications on behalf of the company about its medicines.
8. Healthcare Professionals Who Are Members of Committees That Set Formularies of
Develop Clinical Practice Guidelines
a. Companies must require any healthcare professional who is a member of a
committee that sets formularies or develops clinical guidelines and also serves as
a speaker or commercial consultant for the company to disclose to the committee
the existence and nature of his or her relationship with the company.
9. Scholarships and Educational Funds
a. Financial assistance for scholarships or other educational funds to permit medical
students, residents, fellows, and other healthcare professionals in training to
attend educational conferences may only be offered by the academic or training
institution.
10. Prohibition of Non-Educational and Practice-Related Items
a. Providing items for healthcare professionals’ use that do not advance disease or
treatment education are prohibited. Examples include but are not limited to:
pens, note pads, mugs and similar “reminder” items with company or product
logos.
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b. Items intended for personal benefit of healthcare professionals (such as floral
arrangements, artwork, music CDs or tickets to a sporting event) are prohibited.
c. Payments in cash or cash equivalents (such as gift certificates) are prohibited.
11. Educational Items
a. Items designed primarily for education of patients or healthcare professionals
must be $100 or less in value.
b. Items designed primarily for the education of patients or healthcare professionals
should not be offered on more than an occasional basis.
12. Independence and Decision Making
a. No grants, scholarships, subsidies, support, consulting contracts, or educational
or practice related items should be provided or offered to a healthcare
professional in exchange for prescribing products or for a commitment to
continue prescribing products.
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APPENDIX 4

Final Typology for Source of Regulations

Federal Regulations
1. Office of Inspector General (OIG)
2. Federal Trade Commission (FTC)
3. Division of Drug Marketing and Communication (DDMAC)

Industry Regulations
Pharmaceutical Research and Manufacturers of America (PhRMA)
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APPENDIX 5
Table of Regulations
(In ascending order by number)
Regulation
Number
1

2

3

4

5

6
7
8
9
10

11

Description of Regulation
The manufacturer, sales representatives, or other agents of
the company, may not offer payment or anything of value
for patient referrals or in return for purchasing
(prescriptions)
Manufacturer should identify any remunerative
relationship between itself (and its representatives) and
persons or entities in a position to generate federal health
care business for the manufacturer directly or indirectly
When providing information to decision-makers,
prescribers, or patients, the information must be complete,
accurate and not misleading
Manufacturer is prohibited from coupling a service that
has no independent value in tandem with another service
or program that confers a benefit on a referring provider
Sales and marketing functions are prohibited from
providing grants, nor can it be involved in any aspect of
grant making
Manufacturer should have no control over the speaker or
content of the educational presentation
Manufacturer must document grant making and
educational presentation procedures and regularly monitor
Any payments to cover the costs of "converting" from a
competitor's product is prohibited
Selective offers of remuneration (i.e., offers made to some
but not all purchasers) are prohibited
Relationships with formulary committee members should
not include any renumeration from a manufacturer or its
agents, nor to influence formulary decisions which are
exclusive or restricted status
Relationships with physicians and other persons and
entities in a position to make or influence referrals should
not influence the referral, ordering, or prescribing of the
manufacturers products
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If goods or services provided by the manufacturers
eliminate an expense that the physician would have
otherwise incurred (i.e., have independent value to the
physician), or if items or services are sold to a physician at
less than their fair market value, the arrangement is
prohibited
"Switching" arrangements involve pharmaceuticcal
manufacturers offering physicians or others cash payments
or other benefits each time a patient's prescription is
changed to the manufacturer's product from a competing
product, is prohibited
Consulting and advisory payments whereby
pharmaceutical manufacturers frequently engage
physicians and other health care professionals to furnish
personal services as consultants or advisers to the
manufactures must be at fair market value to small
numbers of physicians for bona fide consulting or
advisory services
Compensating physicians for services directly or
indirectly related to sales and marketing activities such as
speaking, certain research, or preceptor or “shadowing”
services is prohibited
Payments for detailing (i.e., compensating physicians for
time spent listening to sales representatives market
pharmaceutical products), is prohibited
Payments for time spent accessing web sites to view or
listen to marketing information or perform “research” is
prohibited
Entertainment, recreation, travel and meals in association
with information or marketing/ sales presentations are
prohibited
Gifts, gratuities, and other business courtesies are
prohibited
Promotional materials provided to healthcare professionals
by or on behalf of a company should make properly
substantiated claims and reflect the balance between risks
and benefits
Promotional materials provided to healthcare professionals
by or on behalf of a company should be consistent with all
other Food and Drug Administration (FDA) requirements
governing such communications
Occasional meals may be offered as a business courtesy to
healthcare professionals (including members of their staff)
attending sales/ marketing presentations provided the meal
is modest as judged by local standards
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Occasional meals may be offered as a business courtesy to
healthcare professionals (including members of their staff)
attending sales/ marketing presentations as long as the
meeting is not part of an entertainment or recreational
event
Occasional meals may be offered as a business courtesy to
healthcare professionals (including members of their staff)
attending sales/ marketing presentations so long as the
presentations provide scientific or educational value.
Meals offered in connection with informational
presentations made by field sales representatives or their
immediate managers should also be limited to in-office or
in-hospital settings
Inclusion of a healthcare professional's spouse or other
guest in a meal accompanying an informational
presentation made by or on behalf of a company is
prohibited
Offering "take-out" meals or meals to be eaten without a
company representative being present is prohibited
Companies are prohibited from providing any
entertainment or recreational items including tickets to
theatre or sporting events, sporting equipment, or leisure
and vacation trips
Giving of any subsidy directly to a healthcare professional
by a company is prohibited
Any financial support should be given to the CME
provider, which, in turn, can use the money to reduce the
overall CME registration fee for all participants
The company is prohibited to provide any advice or
guidance to the CME provider, even if asked by the
provider, regarding the content or faculty for a particularly
CME program funded by the company
Financial support is prohibited for the costs of travel,
lodging, or other personal expenses of non-faculty
healthcare professionals attending CME
Funding should not be offered to compensate for the time
spent by healthcare professionals participating in the CME
event
A company should not provide meals directly at CME
events, except that a CME provider at its own discretion
may apply the financial support provided by a company
for CME event to provide meals for all participants
Any subsidy or financial support for professional meetings
may not be provided to a healthcare professional
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Financial support for professional meetings should be
given directly to the conference’s sponsor, which, in turn,
can use the money to reduce the overall conference
registration fee for all attendees
When companies underwrite medical conferences or
meetings other than their own, responsibility for and
control over the selection of content, faculty, educational
methods, materials, and venue belongs to the organizers of
the conference and may not be influence by the sponsoring
company
Financial support for the costs of travel, lodging, or other
personal expenses are prohibited
Consulting agreements are prohibited to serve as either
inducements or rewards for prescribing or recommending
a particular medicine or course of treatment
A written contract must specify the nature of the
consulting services to be provided and the basis for
payment of those services
A legitimate need for the consulting services must be
clearly identified in advance of requesting the services and
entering into arrangements with the prospective
consultants
The criteria for selecting consultants must be directly
related to the identified purpose and the persons
responsible for selecting the consultants have the expertise
necessary to evaluate whether the particular healthcare
professionals meet those criteria
It is required that the number of healthcare professionals
retained is not greater than the number reasonably
necessary to achieve the identified purpose
The retaining company must maintain records concerning
and makes appropriate use of the services provided by
consultants
The venue and circumstances of any meeting with
consultants are conducive to the consulting services and
activities related to the services are the primary focus of
the meeting; specifically, resorts are not appropriate
venues
Companies are prohibited to provide recreational or
entertainment events in conjunction with consultant/
educational meetings
It is prohibited to pay honoraria or travel or lodging
expenses to non-faculty and non-consultant healthcare
professional attendees at company-sponsored meetings,
including attendees who participate in interactive sessions
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Company decisions regarding the selection or retention of
healthcare professionals as speakers should be made based
on defined criteria such as general medical expertise and
reputation
Each company should cap the total amount of annual
compensation it will pay to an individual healthcare
professional in connection with all speaking arrangements
Each company should develop policies addressing the
appropriate use of speakers, including utilization of
speakers after training and the appropriate number of
engagements for any particular speaker over time
Speakers and their materials must clearly identify the
company that is sponsoring the presentation
Companies must monitor speaker programs for
compliance with FDA regulatory requirements for
communications on behalf of the company about its
medicines
Companies must require any healthcare professional who
is a member of a committee that sets formularies or
develops clinical guidelines and also serves as a speaker or
commercial consultant for the company to disclose to the
committee the existence and nature of his or her
relationship with the company
Financial assistance for scholarships or other educational
funds to permit medical students, residents, fellows, and
other healthcare professionals in training to attend
educational conferences may only be offered by the
academic or training institution
Providing items for healthcare professionals’ use that do
not advance disease or treatment education is prohibited.
Examples include but are not limited to: pens, note pads,
mugs and similar “reminder” items with company or
product logos
Items intended for personal benefit of healthcare
professionals (such as floral arrangements, artwork, music
CDs or tickets to a sporting event) are prohibited
Payments in cash or cash equivalents (such as gift
certificates) are prohibited
Items designed primarily for education of patients or
healthcare professionals must be $100 or less in value
Items designed primarily for the education of patients or
healthcare professionals should not be offered on more
than an occasional basis
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No grants, scholarships, subsidies, support, consulting
contracts, or educational or practice related items should
be provided or offered to a healthcare professional in
exchange for prescribing products or for a commitment to
continue prescribing products
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APPENDIX 6
Selling Activities
Relationship Building (Reid, Plank, and Minton 1997)
x1: Ability to ask probing questions
x2: Listened to customer
x3: Ability to make a charismatic presentation
x4: Ability to work well with other people who are involved in the purchase
(Adapted from industry interviews and focus groups)
x16: Follow up with customer
Getting to Buy (Reid, Plank, and Minton 1997)
x5: Gain participation and got customer involved in the sales presentation
x6: Ability to use analogies and similes in his/her presentation to help customer see how it relates to
his/her situation
x7: Ability to link his/her product/service attributes to customer needs
x8: Could differentiate his/her product/service from the competition
x9: Ability to do “homework” on customer
x10: Ability to handle objections raised by customer
Planning
(Moncrief, Marshall, and Lassk 2006)
x11: Search out new leads
x12: Pre-call planning/ targeting
x17: Administrative activities/ documentation
(Adapted from industry interviews and focus groups)
x13: Conduct targeting activities
x14: Designing sales plan
x15: Business planning
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APPENDIX 7
Survey Cover Letter

Research Study Title: The Effect of Regulation on Selling Activities
Primary Investigator: John F. Riggs, D.B.A., Doctoral Candidate, A.B.D.

Dear Participant,
I am inviting you participate in a research project to study the effect of regulation on
selling activities. Along with this letter is a short questionnaire that asks a variety of
questions about how you perceive specific regulations affect your selling activities. The
questionnaire contains only twenty (20) items and will take about 15 minutes to
complete. I guarantee that your responses will not be identified with you personally, are
blinded, and completely anonymous.
The results of this project will be used to complete my doctoral dissertation. Through
your participation I hope to develop a taxonomy (classification scheme) of regulations
that accurately reflects their effect on selling activities by pharmaceutical sales people. I
hope to share my results by publishing them in a scientific journal as well as various
public press outlets.
This project has been approved by the Institutional Review Board (IRB) at Kennesaw
State University, Kennesaw, Georgia.
Sincerely,
John F. Riggs
Doctor of Business Administration, Doctoral Candidate, A.B.D.
Kennesaw State University
Email: 610ksudba@comcast.net
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Survey Version #1
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APPENDIX 8
Factor Analysis Final Groupings

Factor 1
Customer Relationships through Communication
x1: Ability to ask probing questions
x2: Listened to customer
x3: Ability to make a charismatic presentation
x4: Ability to work well with other people who are involved in the
purchase
x16: Follow up with customer
Factor 2
Core Selling Skills
x5: Gain participation and got customer involved in the sales
presentation
x6: Ability to use analogies and similes in his/her presentation to help
customer see how it relates to his/her situation
x7: Ability to link his/her product/service attributes to customer needs
x8: Could differentiate his/her product/service from the competition
x9: Ability to do “homework” on customer
x10: Ability to handle objections raised by customer
Factor 3
Planning
x11: Search out new leads
x12: Pre-call planning/ targeting
x13: Conduct targeting activities
x14: Designing sales plan

